☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware |
82-2726724 | |
State or other jurisdiction of incorporation or organization |
(I.R.S. Employer Identification Number) |
Title of each class |
Trading Symbols |
Name of each exchange on which registered | ||
C lass A Common Stock, par value $0.0001 per share |
HYZN |
NASDAQ Capital Market | ||
Warrants, each whole warrant exercisable for one share of Class A common stock, $0.0001 par value, at an exercise price of $11.50 per share |
HYZNW |
NASDAQ Capital Market |
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ | |||
Emerging growth company |
☒ |
PCAOB ID: 0185 |
Auditor Name: KPMG LLP |
Auditor Location: Rochester, New York |
• |
our ability to commercialize our products and strategic plans, including our ability to establish facilities to produce our vehicles or secure hydrogen supply in appropriate volumes, at competitive costs or with competitive emissions profiles; |
• |
our ability to effectively compete in the heavy-duty transportation sector, and withstand intense competition and competitive pressures from other companies worldwide in the industries in which we operate; |
• |
our ability to convert non-binding memoranda of understanding into binding orders or sales (including because of the current or prospective resources of our counterparties) and the ability of our counterparties to make payments on orders; |
• |
our ability to invest in hydrogen production, distribution and refueling operations to supply our customers with hydrogen at competitive costs to operate their fuel cell electric vehicles; |
• |
disruptions to the global supply chain, including as a result of the COVID-19 pandemic and geopolitical events, and shortages of raw materials, and the related impacts on our third party suppliers and assemblers |
• |
our ability to maintain the listing of our common stock on NASDAQ; |
• |
our ability to raise financing in the future; |
• |
our ability to retain or recruit, or changes required in, our officers, key employees or directors; |
• |
our ability to protect, defend or enforce intellectual property on which we depend; and |
• |
the impacts of legal proceedings, regulatory disputes and governmental inquiries. |
4 |
||||
4 |
||||
32 |
||||
66 |
||||
66 |
||||
66 |
||||
66 |
||||
67 |
||||
67 |
||||
68 |
||||
68 |
||||
83 |
||||
84 |
||||
117 |
||||
117 |
||||
119 |
||||
119 |
||||
120 |
||||
120 |
||||
129 |
||||
135 |
||||
137 |
||||
142 |
||||
144 |
||||
144 |
||||
147 |
||||
148 |
• | Higher fuel efficiency: |
• | Potentially lower cost of fuel non-renewable hydrocarbon resources, including diesel fuel. Because the cost to transport hydrogen can be significant, close-to-fleet |
• | Improved performance |
• | Reduced noise |
• | Zero GHG emissions near-zero-emission powertrain, as there is no combustion occurring in hydrogen fuel cells. |
• | Significant local area health benefits: |
• | Reduced TCO |
• | Seamless transition from ICE is possible |
• | Increased driving range: 300-mile range depending on duty cycle. This range is greater than the distance advertised by many manufacturers for their heavy-duty BEVs. |
• | Increased payloads: |
• | Faster refueling times: |
• | Lower infrastructure hurdles: build-out is a challenge for both FCEV and BEV HD and MD commercial vehicles, but we believe hydrogen has the infrastructure advantage when considering the required cost and time to build-out the production, distribution and refueling infrastructure capacities to support each. Hydrogen fuel can be produced locally from a wide variety of resources and, when produced with low carbon intensity production methods and used to power fuel cells, results in zero direct GHG emissions. Clean hydrogen infrastructure can likely be built efficiently by building hydrogen production and dispensing in a modular fashion paired with and close to fleet deployments as the market develops from a breadth of locally available feedstocks, in most cases fully independent from major infrastructure constraints like the electricity grid. Comparatively, our analysis shows that any sizable HD and MD commercial truck BEV fleet deployment in many regions of the world will likely require significant electric charging infrastructure and electricity grid investment to bring substantial rapid charging to bear. For instance, charging just 100 Class 8 BEV trucks, each with battery capacity of 500kWh with megawatt chargers, would likely require at least 50 MW of power to support a back-to-base re-charging time. In addition to investing in last-mile charging infrastructure, significant investment would likely also need to be made in transmission and distribution infrastructure to deliver the power needed to charge high-capacity batteries in HD and MD commercial BEV fleets. In summary, we believe that the combination of availability, energy density, and local production will allow low carbon hydrogen to acquire substantial market share for powering HD and many MD commercial vehicles. |
• | Proven hydrogen fuel cell technology and vehicle electrification experience |
• | Highly experienced and proven team. |
• | Strong fit with the comme r cial vehicle market Market Opportunity ” “ Competition |
• | Vertical integration in key FCEV components and targeted assembly capabilities. |
• | Asset-light, first mover approach to vehicle assembly |
• | Partnered approach to bringing competitive hydrogen fuel to market located close to fleet deployments low-to-negative |
• | Upfit of commonly used vehicles – electrifying existing OEM vehicle platforms that our customers operate in their fleets today instead of introducing new cab and chassis designs increases the likelihood that drivers will be comfortable behind the wheel from day one. It further provides entry into international markets, as regional differences in vehicle designs are common, making upfit of existing platforms a faster pathway to putting familiar vehicles into customers’ hands. |
• | Trial programs – before purchase, customers may participate in a paid trial to test our vehicles in daily operations. |
• | Fuel access – during trial and after purchase, Hyzon aims to provide access to fueling infrastructure through a mobile refueler or local hydrogen production plant. |
• | Existing carrier and service partners – thanks to a modular vehicle assembly approach, Hyzon can quickly train technical service providers to perform maintenance on the vehicle. |
• | Leasing service – customers can participate in Hyzon’s leasing service, paying a stable and predictable monthly bundled rate for vehicle, fuel, and service. |
• | the zero-emission vehicle; |
• | scheduled preventative maintenance; and |
• | hydrogen supply. |
• | advanced materials for fuel cell stack, MEA and bipolar plate; |
• | novel solid-state battery for optimizing FCEV performance; |
• | high efficiency multi-motor drive systems with torque vectoring; |
• | advanced driver assistance systems and autonomous driving technology; |
• | purpose-built vehicle platforms with light-weight materials; |
• | advanced production technologies in vehicle electrification components; |
• | green hydrogen hubs with hydrogen and electricity produced from renewable resources; and |
• | on-site energy storage with hydrogen and batteries. |
• | Low Carbon Fuel Standard well-to-wheel |
• | Grant and Subsidy Programs zero-emission vehicles and infrastructure technologies. Federal and state grant and subsidy programs are under evaluation for introduction and/or expansion, such as LCFS structures in Oregon and Washington, and the Federal IIJA which includes significant funding opportunities for hydrogen ecosystem enablement, including $8 billion for the establishment of at least four hydrogen hubs across the U.S. |
• | EPA Smartway |
• | The European Union currently maintains a key funding programme for research and innovation with a total budget of €95.5Bn, including €15.1Bn allocated for Climate, Energy and Mobility, including clean hydrogen and zero-emission road transport. The EU also has an Innovation Fund which provides €10Bn of support through 2030 for the commercial demonstration of innovative low-carbon technologies. |
• | The UK has introduced a Net Zero Hydrogen Fund (“NZHF”) of £240MM to support the commercial deployment of new low carbon hydrogen production projects. The UK additionally created the Department for Transport Zero Emission Road Freight Trials (“ZERFT”) £20MM to demonstrate zero-emission freight and stimulate transition through road freight trials. |
• | Germany introduced various subsidies totaling approximately €3Bn up to 10 years to support the penetration of zero emission vehicles and green hydrogen production. These subsidies will contribute to the EU environmental objectives, in line with the European Green Deal. |
• | China’s central government is initiating a four-year pilot program, and select cities will be elected to carry out research and development and application demonstrations of FCEVs. This pilot program seeks to encourage innovation and to stimulate the development of hydrogen and the FCEV industry in China. The Chinese central government will reward successful pilot cities and details of those benefits and programs are to be published by the government in a separate policy document. |
• | Electronic Stability Control. loss-of-control. |
• | Air Brake Systems. |
• | Electric Vehicle Safety. |
• | Flammability of Interior Materials. |
• | Seat Belt Assemblies and Anchorages. |
• | Tire Pressure Monitoring System. |
• | Roof Crush Resistance. |
• | Minimum Sound Requirements for Hybrid and Electric Vehicles. |
• | Crash Tests for High-Voltage and Hydrogen Fuel System Integrity. |
• | Step, Handhold and Deck Requirements. |
• | Auxiliary Lamps. |
• | Speedometer. |
• | Electromagnetic Compatibility and Interference. |
• | Lane Departure Warning System. |
• | Electric Vehicle Safety. in-use and post-crash. |
• | Hydrogen Fuel Cell Vehicle Safety. in-use and post-crash. |
• | Our business model has yet to be tested and we may fail to commercialize our strategic plans. |
• | We recently completed the Business Combination with Decarbonization Plus Acquisition Corporation (“DCRB”) in which we raised gross proceeds net of redemption and transaction costs totaling approximately $512.9 million. Nevertheless, we may need to raise additional funds, and these funds may not be available on terms favorable to us or our stockholders or at all when needed. |
• | Increases in costs, disruption of supply or shortage of raw materials, could harm our business. |
• | We qualify as an “emerging growth company’ as defined in Section 2(a)(19) of the Securities Act, as modified by the JOBS Act, and we take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act. As a result, our shareholders may not have access to certain information they deem important. |
• | We have identified a material weakness in our internal control over financial reporting which, if not corrected, could affect the reliability of our consolidated financial statements and have other adverse consequences. |
• | Our Class A Common Stock commenced trading on the NASDAQ Global Select Market on July 19, 2021, and we have limited experience operating as a publicly traded company. We need to implement various policies, procedures and controls pertaining to our operations and governance as required by SEC and NASDAQ rules and regulations. |
• | We have a limited number of current customers, and there is no assurance as to whether our sales pipeline will result in sales and revenues, or that we will be able to convert non-binding letters of intent or memoranda of understanding into orders or sales (including because of the current or prospective financial resources of the counterparties to our non-binding memoranda of understanding and letters of intent, the liability accounting for our warrants or customer contractual demands), or that we will be able to identify additional potential customers and convert them to paying customers. |
• | We also face and will continue to face significant competition in all aspects of our business and operations, and many of our current and future competitors have or will have significantly more resources than us, and may outcompete us for customers, employees, and suppliers. |
• | We may not succeed in investing in hydrogen production, distribution and refueling operations critical to supplying our customers with hydrogen to operate our FCEVs either at all or in part, and/or at the cost required to achieve TCO for potential Hyzon FCEV customers to drive their purchases of our trucks. |
• | There is no assurance that there will be, or that we will be able to supply, hydrogen at prices or with an emissions profile that allow our FCEVs to be competitive with commercial vehicles powered by other energy sources. |
• | We may face legal challenges and other resistance attempting to sell our vehicles which could materially adversely affect our sales and costs. Additionally, unfavorable publicity, or a failure to respond effectively to adverse publicity, could harm our reputation and adversely affect our business. |
• | If we engage in mergers or acquisitions, we may assume liabilities – both disclosed and undisclosed – by contract or under operation of law of the target or acquired company which could materially adversely affect our business and financial results. |
• | To date, we have produced only technology validation or evaluation FCEVs and there is no assurance that we will be able to establish and operate facilities capable of producing our FCEVs in appropriate volumes and at competitive costs or at all. |
• | We have limited experience servicing our FCEVs. If we are unable address the service requirements of our customers, our business will be materially and adversely affected. Additionally, insufficient warranty reserves to cover future warranty claims could materially adversely affect our business, prospects, financial condition, and operating results. |
• | Threats to information technology, including unauthorized control of our vehicles or interruption of our systems, could adversely affect our business. |
• | We may be unsuccessful in meeting various local, national and international safety and emissions rules and regulations for our products. |
• | We depend on third parties, including Horizon, for supply of key inputs and components for our products. |
• | We will depend on Horizon as a sole source supplier for our fuel cell systems, until such time we are able to commence manufacturing fuel cell systems inhouse. |
• | the premium in the anticipated initial purchase prices of our commercial vehicles over those of comparable vehicles powered by ICE or other alternative energy sources, both including and excluding the effect of possible government and other subsidies and incentives designed to promote the purchase of vehicles powered by clean energy; |
• | the total cost of ownership of the vehicle over its expected life, which includes the initial purchase price and ongoing operating costs, including hydrogen supply, price, and maintenance costs; |
• | access to hydrogen supply and refueling stations locally and nationally, and related infrastructure costs; |
• | the availability and terms of financing options for our customers to purchase or lease our vehicles; |
• | the availability of tax and other governmental incentives to purchase and operate non-carbon emitting vehicles, and future regulations requiring increased use of non-carbon emitting vehicles; |
• | government regulations and economic incentives promoting or mandating fuel efficiency and alternate forms of energy; |
• | prices for hydrogen, diesel, natural gas, electricity and other sources of power for vehicles, and volatility in the cost of diesel or a prolonged period of low gasoline and natural gas costs that could decrease incentives to transition to vehicles powered by alternative energy sources; |
• | the cost and availability of other alternatives to diesel or natural gas fueled vehicles, such as electric vehicles; |
• | corporate sustainability initiatives and environmental, social and governance (“ESG”) policies; |
• | perceptions about hydrogen, safety, design, performance, reliability and cost, especially if adverse events or accidents occur that are linked to the quality or safety of hydrogen-powered vehicles, or the safety of production, transportation or use of hydrogen generally; |
• | the quality and availability of service for our commercial vehicles, including the availability of replacement parts; |
• | the ability of our customers to purchase adequate insurance for our vehicles; and |
• | macroeconomic factors. |
• | cease development, sales or use of our products that incorporate or are covered by the asserted IP; |
• | pay substantial damages, including through indemnification obligations; |
• | obtain a license from the owner of the asserted IP, which license may not be available on reasonable terms or at all; or |
• | redesign one or more aspects of our hydrogen-powered commercial vehicles or hydrogen fuel cell systems. |
• | any patent applications we submit or currently have pending may not result in the issuance of patents; |
• | the scope of our issued patents, including our patent claims, may not be broad enough to protect our proprietary rights; |
• | our issued patents may be challenged or invalidated; |
• | our employees, customers or business partners may breach their confidentiality, non-disclosure and non-use obligations to us; |
• | We fail or are determined by a court of competent jurisdiction to have failed to make reasonable efforts to protect our trade secrets; |
• | third parties may independently develop technologies that are the same or similar to ours; |
• | we may not be successful in enforcing our IP portfolio against third parties who are infringing or misappropriating such IP, for a number of reasons, including substantive and procedural legal impediments; |
• | our trademarks may not be valid or enforceable, and our efforts to police unauthorized use of our trademarks may be deemed insufficient to satisfy legal requirements throughout the world; |
• | the costs associated with enforcing patents, confidentiality and invention agreements or other IP may make enforcement impracticable; and |
• | current and future competitors may circumvent or design around our IP. |
• | actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; |
• | changes in the market’s expectations about our operating results; |
• | success of competitors; |
• | our operating results failing to meet the expectation of securities analysts or investors in a particular period; |
• | changes in financial estimates and recommendations by securities analysts concerning us or the market in general; |
• | operating and stock price performance of other companies that investors deem comparable to us; |
• | our ability to market new and enhanced products and technologies on a timely basis; |
• | changes in laws and regulations affecting our business; |
• | our ability to meet compliance requirements; |
• | commencement of, or involvement in, litigation; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of shares of our Class A Common Stock available for public sale; |
• | any major change in our Board or management; |
• | investors engaged in short selling our Class A Common Stock; |
• | sales of substantial amounts of Class A Common Stock by our directors, executive officers or significant stockholders or the perception that such sales could occur; and |
• | general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. |
• | a limited availability of market quotations for our securities; |
• | reduced liquidity for our securities; |
• | a determination that our Class A Common Stock is a “penny stock” which will require brokers trading in our Class A Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
• | a limited amount of news and analyst coverage; and |
• | a decreased ability to issue additional securities or obtain additional financing in the future. |
• | may significantly dilute the equity interests of our investors; |
• | may subordinate the rights of holders of Class A Common Stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | could cause a change in control if a substantial number of shares of our Class A Common Stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
• | may adversely affect prevailing market prices for our units, Class A Common Stock and/or warrants. |
• | our Board is divided into three classes with staggered terms; |
• | the right of our Board to issue preferred stock without stockholder approval; |
• | restrictions on the right of stockholders to remove directors without cause; and |
• | restrictions on the right of stockholders to call special meetings of stockholders. |
Period |
Total Number of Units Purchased (1) |
Average Price Paid per Unit |
Total Number of Units Purchased Under Announced Programs (2) |
Approximate Dollar Value of Units That May Yet be Purchased Under Announced Programs (in thousands) |
||||||||||||
October 1, 2021 through October 31, 2021 |
— | $ | — | — | $ | — | ||||||||||
November 1, 2021 through November 30, 2021 |
40,196 | $ | 2.35 | 40,196 | $ | 4,906 | ||||||||||
December 1, 2021 through December 31, 2021 |
216,781 | $ | 2.05 | 216,781 | $ | 4,460 | ||||||||||
|
|
|
|
|||||||||||||
Total/Average |
256,977 |
$ |
2.10 |
256,977 |
||||||||||||
|
|
|
|
(1) | Units purchased consist of public warrants repurchased in the open market. |
(2) | On November 17, 2021, the Company’s Board of Directors authorized the purchase of up to $5.0 million of its outstanding common stock and/or public warrants. |
• | Our workforce COVID-19, we established protocols to help protect the health and safety of our workforce. We will continue to stay up-to-date |
• | Operations and Supply Chain. zero-emission heavy commercial vehicles despite these challenges. In the future, we may experience supply chain disruptions from related or third-party suppliers and any such supply chain disruptions could cause delays in our development and delivery timelines. We continue to monitor the situation for any potential adverse impacts and execute appropriate countermeasures, where possible. To mitigate the impact of supply chain disruptions that we were experiencing in 2021, which disproportionately impacted our business in Europe, we focused on fulfilling orders for our vehicles in China where supply chain disruptions were not as significant. |
Year Ended December 31, |
For the period January 21, 2020 (Inception) – December 31, |
|||||||||||||||
2021 |
2020 |
$ Change |
% Change |
|||||||||||||
Revenue |
$ |
6,049 |
$ |
— |
$ |
6,049 |
NM |
|||||||||
Operating expense: |
||||||||||||||||
Cost of Revenue |
21,191 | — | 21,191 | NM | ||||||||||||
Research and development |
16,443 | 1,446 | 14,997 | 1037 | % | |||||||||||
Selling, general and administrative |
69,792 | 12,785 | 57,007 | 446 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total operating expense |
107,426 | 14,231 | 93,195 | 655 | % | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss from operations |
(101,377 |
) |
(14,231 |
) |
(87,146 |
) |
612 |
% | ||||||||
Other income (expense): |
||||||||||||||||
Change in fair value of private placement warrant liability |
4,167 | — | 4,167 | NM | ||||||||||||
Change in fair value of earnout liability |
84,612 | — | 84,612 | NM | ||||||||||||
Foreign currency exchange loss and other expense |
(1,452 | ) | (108 | ) | (1,344 | ) | 1244 | % | ||||||||
Interest expense, net |
(5,235 | ) | (37 | ) | (5,198 | ) | 14049 | % | ||||||||
Total other income (expense) |
82,092 |
(145 |
) |
82,237 |
-56715 |
% | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ |
(19,285 |
) |
$ |
(14,376 |
) |
$ |
(4,909 |
) |
34 |
% | |||||
|
|
|
|
|
|
|
|
|||||||||
Less: Net loss attributable to noncontrolling interest |
(5,439 | ) | (105 | ) | (5,334 | ) | 5080 | % | ||||||||
Net loss attributable to Hyzon |
$ |
(13,846 |
) |
$ |
(14,271 |
) |
$ |
425 |
-3 |
% | ||||||
|
|
|
|
|
|
|
|
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
Net loss |
$ | (19,285 | ) | $ | (14,376 | ) | ||
Plus: |
||||||||
Interest expense, net |
5,235 | 37 | ||||||
Income tax expense (benefit) |
— | — | ||||||
Depreciation and amortization |
1,140 | 185 | ||||||
|
|
|
|
|||||
EBITDA |
$ |
(12,910 |
) |
$ |
(14,154 |
) | ||
Adjusted for: |
||||||||
Change in fair value of private placement warrant liability |
(4,167 | ) | — | |||||
Change in fair value of earnout liability |
(84,612 | ) | — | |||||
Stock-based compensation |
15,768 | 9,983 | ||||||
Executive transition charges (1) |
13,860 | — | ||||||
Business combination transaction expenses (2) |
6,533 | — | ||||||
Regulatory and legal matters (3) |
1,147 | — | ||||||
Acquisition-related expenses (4) |
591 | — | ||||||
|
|
|
|
|||||
Adjusted EBITDA |
$ |
(63,790 |
) |
$ |
(4,171) |
|||
|
|
|
|
(1) | Executive transition charges include stock-based compensation costs of $13.4 million and salary expense of $0.5 million related to former CTO’s retirement. |
(2) | Transaction costs of $6.4 million attributable to the liability classified earnout shares and $0.1 million of write-off of debt issuance costs. |
(3) | Regulatory and legal matters include legal, advisory, and other professional service fees incurred in connection with the short-seller analyst article from September 2021, and investigations and litigation related thereto. |
(4) | Acquisition-related expenses incurred for potential and actual acquisitions that are unrelated to the current operations and neither are comparable to the prior period nor predictive of future results. |
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) - December 31, 2020 |
|||||||
Net cash used in operating activities |
$ | (95,191 | ) | $ | (1,182 | ) | ||
Net cash used in investing activities |
(23,706 | ) | (553 | ) | ||||
Net cash provided by financing activities |
550,692 | 18,894 |
Total |
2022 |
2023 |
2024 |
2025 |
2026 and thereafter |
|||||||||||||||||||
Horizon IP Agreement (1) |
$ | 3,146 | $ | 3,146 | $ | — | $ | — | $ | — | $ | — | ||||||||||||
Finance Lease Obligation (2) |
688 | 448 | 240 | — | — | — | ||||||||||||||||||
Operating Lease Obligations (3) |
12,160 | 1,978 | 1,894 | 1,806 | 1,745 | 4,737 | ||||||||||||||||||
Purchase Obligations (4) |
33,969 | 29,069 | 4,900 | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
$ |
49,963 |
$ |
34,641 |
$ |
7,034 |
$ |
1,806 |
$ |
1,745 |
$ |
4,737 |
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(1) | The final $3.1 million payment due to Jiangsu Horizon Powertrain, pursuant to the terms of the Horizon IP Agreement. Please see the section below entitled, “ Material Transactions with Related Parties |
(2) | The minimum lease payments for the finance lease obligation. |
(3) | The minimum lease payments for operating lease obligations. The operating leases relate to real estate and vehicles. No asset is leased from any related party. |
(4) | The Company enters into commitments under non-cancellable or partially cancellable purchase orders or vendor agreements in the ordinary course of business for FCEV components. |
• | Fair Value of Common Stock. |
• | Expected Term. |
• | Expected Volatility. |
• | Risk-Free Interest Rate. zero-coupon securities with maturities consistent with the estimated expected term. |
• | Expected Dividend Yield. |
• | Recent arms-length transactions involving the sale or transfer of our common stock; |
• | Our historical financial results and future financial projections; |
• | The market value of equity interests in substantially similar businesses, which equity interests can be valued through nondiscretionary, objective means; |
• | The lack of marketability of our common stock; |
• | The likelihood of achieving a liquidity event, such as the business combination, given prevailing market conditions; |
• | Industry outlook; and |
• | General economic outlook, including economic growth, inflation and unemployment, interest rate environment and global economic trends. |
December 31, 2021 |
December 31, 2020 |
|||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | 445,146 | $ | 17,139 | ||||
Accounts receivable |
2,598 | — | ||||||
Related party receivable |
264 | — | ||||||
Inventory |
19,245 | — | ||||||
Prepaid expenses and other current assets |
27,970 | 848 | ||||||
|
|
|
|
|||||
Total current assets |
495,223 | 17,987 | ||||||
Property, plant, and equipment, net |
14,311 | 418 | ||||||
Right-of-use assets |
10,265 | 1,656 | ||||||
Investment s in equity securities |
4,948 | 122 | ||||||
Other assets |
5,430 | 822 | ||||||
|
|
|
|
|||||
Total Assets |
$ |
530,177 |
$ |
21,005 |
||||
|
|
|
|
|||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ | 8,430 | $ | 215 | ||||
Accrued liabilities |
6,026 | 1,062 | ||||||
Related party payables |
3,633 | 560 | ||||||
Contract liabilities |
11,230 | 2,608 | ||||||
Current portion of lease liabilities |
1,886 | 618 | ||||||
|
|
|
|
|||||
Total current liabilities |
31,205 |
5,063 |
||||||
|
|
|
|
|||||
Long term liabilities |
||||||||
Lease liabilities |
8,830 | 1,181 | ||||||
Private placement warrant liability |
15,228 | — | ||||||
Earnout liability |
103,761 | — | ||||||
Other liabilities |
1,296 | — | ||||||
|
|
|
|
|||||
Total liabilities |
$ |
160,320 |
$ |
6,244 |
||||
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 1 4 ) |
||||||||
Stockholders’ Equity |
||||||||
Common stock, $0.0001 par value; 400,000,000 shares authorized, 247,758,412 and 166,125,000 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively . |
25 | 17 | ||||||
Additional paid-in capital |
403,016 | 29,122 | ||||||
Accumulated deficit |
(28,117 | ) | (14,271 | ) | ||||
Accumulated other comprehensive income (loss) |
373 | (16 | ) | |||||
|
|
|
|
|||||
Total Hyzon Motors Inc. stockholders’ equity |
375,297 | 14,852 | ||||||
Noncontrolling interest |
(5,440 | ) | (91 | ) | ||||
|
|
|
|
|||||
Total Stockholders’ Equity |
369,857 |
14,761 |
||||||
|
|
|
|
|||||
Total Liabilities and Stockholders’ Equity |
$ |
530,177 |
$ |
21,005 |
||||
|
|
|
|
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
Revenue |
$ |
6,049 |
$ |
— |
||||
Operating expense: |
||||||||
Cost of revenue |
21,191 | — | ||||||
Research and development |
16,443 | 1,446 | ||||||
Selling, general , and administrative |
69,792 | 12,785 | ||||||
|
|
|
|
|||||
Total operating expenses |
107,426 | 14,231 | ||||||
|
|
|
|
|||||
Loss from operations |
(101,377 |
) |
(14,231 |
) | ||||
|
|
|
|
|||||
Other income (expense): |
||||||||
Change in fair value of private placement warrant liability |
4,167 | — | ||||||
Change in fair value of earnout liability |
84,612 | — | ||||||
Foreign currency exchange loss and other expense |
(1,452 | ) | (108 | ) | ||||
Interest expense, net |
(5,235 | ) | (37 | ) | ||||
|
|
|
|
|||||
Total other income (expense) |
82,092 |
(145 |
) | |||||
|
|
|
|
|||||
Net loss |
$ |
(19,285 |
) |
$ |
(14,376 |
) | ||
Less: Net loss attributable to noncontrolling interest |
(5,439 | ) | (105 | ) | ||||
|
|
|
|
|||||
Net loss attributable to Hyzon |
$ |
(13,846 |
) |
$ |
(14,271 |
) | ||
Comprehensive loss: |
||||||||
Net loss |
$ |
(19,285 |
) |
$ |
(14,376 |
) | ||
Foreign currency translation adjustment |
479 | (20 | ) | |||||
|
|
|
|
|||||
Comprehensive loss |
$ |
(18,806 |
) |
$ |
(14,396 |
) | ||
|
|
|
|
|||||
Less: Comprehensive loss attributable to noncontrolling interest |
(5,349 | ) | (109 | ) | ||||
|
|
|
|
|||||
Comprehensive loss attributable to Hyzon |
$ |
(13,457 |
) |
$ |
(14,287 |
) | ||
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net loss attributable to Hyzon |
||||||||
Basic |
$ |
(0.07 | ) | $ | (0.09 | ) | ||
Diluted |
$ |
(0.07 | ) | $ | (0.09 | ) | ||
Weighted average common shares outstanding: |
||||||||
Basic |
203,897 | 152,650 | ||||||
Diluted |
203,897 | 152,650 |
Legacy Common Stock |
Common Stock Class A |
Additional Paid-in Capital |
Retained Earnings (Accumulated Deficit) |
Accumulated Other Comprehensive Loss |
Total Hyzon Motors Inc. Stockholders’ Equity (Deficit) |
Noncontrolling Interest |
Total Stockholders’ Equity (Deficit) |
|||||||||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||||||||||
Balance at January 21, 2020 (Inception) |
83,750,000 |
$ |
84 |
— |
$ |
— |
— |
— |
— |
84 |
— |
$ |
84 |
|||||||||||||||||||||||||||
Retroactive application of recapitalization |
(83,750,000 | ) | (84 | ) | 148,405,000 | 15 | 69 | — | — | — | — | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Adjusted balance, beginning of period |
— |
— |
148,405,000 |
15 |
69 |
— |
— |
84 |
— |
84 |
||||||||||||||||||||||||||||||
Issuance of common stock, net of issuance costs of $1,024 (1) |
— | — | 17,277,000 |
2 |
18,474 | — | — | 18,476 | — | 18,476 | ||||||||||||||||||||||||||||||
Conversion of convertible notes (1) |
— | — | 443,000 |
— |
500 | — | — | 500 | — | 500 | ||||||||||||||||||||||||||||||
Stock - |
— | — | — | — | 10,079 | — | — | 10,079 | — | 10,079 | ||||||||||||||||||||||||||||||
Noncontrolling interest capital contribution |
— | — | — | — | — | — | — | — | 18 | 18 | ||||||||||||||||||||||||||||||
Net loss attributable to Hyzon |
— | — | — | — | — | (14,271 | ) | — | (14,271 | ) | — | (14,271 | ) | |||||||||||||||||||||||||||
Net loss attributable to noncontrolling interest |
— | — | — | — | — | — | — | — | (105 | ) | (105 | ) | ||||||||||||||||||||||||||||
Foreign |
— | — | — | — | — | — | (16 | ) | (16 | ) | (4 | ) | (20 | ) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Balance at December 31, 2020 |
— |
$ |
— |
166,125,000 |
$ |
17 |
29,122 |
(14,271 |
) |
(16 |
) |
14,852 |
(91 |
) |
$ |
14,761 |
||||||||||||||||||||||||
Reverse (Note 3) |
— | — | 73,502,303 | 7 | 354,627 | — | — | 354,634 | — | 354,634 | ||||||||||||||||||||||||||||||
Issuance of common stock |
— |
— |
7,234,006 |
1 |
(1 |
) |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||
Exercise of stock options |
— | — | 436,037 | — | 532 | — | — | 532 | — | 532 | ||||||||||||||||||||||||||||||
Stock - |
— | — | — | — | 29,088 | — | — | 29,088 | — | 29,088 | ||||||||||||||||||||||||||||||
Vesting of RSUs |
— | — | 428,107 | — |
— | — | — | — | — | — | ||||||||||||||||||||||||||||||
Common stock issued for the cashless exercise of warrants |
|
|
— |
|
|
|
— |
|
|
|
32,959 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
IP transaction – deemed distribution |
— | — | — |
— | (10,000 | ) | — | — | (10,000 | ) | — | (10,000 | ) | |||||||||||||||||||||||||||
Repurchase of warrants |
— | — | — | — | (540 | ) | — | — | (540 | ) | — | (540 | ) | |||||||||||||||||||||||||||
Issuance of Hongyun Warrants |
— | — | — | — | 188 | — | — | 188 | — | 188 | ||||||||||||||||||||||||||||||
Net loss attributable to Hyzon |
— | — | — | — | — | (13,846 | ) | — | (13,846 | ) | — | (13,846 | ) | |||||||||||||||||||||||||||
Net loss attributable to noncontrolling interest |
— | — | — | — | — | — | — | — | (5,439 | ) | (5,439 | ) | ||||||||||||||||||||||||||||
Foreign currency translation loss |
— | — | — | — | — | — | 389 | 389 | 90 | 479 | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Balance at December 31, 2021 |
— |
$ |
— |
247,758,412 |
$ |
25 |
403,016 |
(28,117 |
) |
373 |
375,297 |
(5,440 |
) |
$ |
369,857 |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Issuance of common stock, net of issuance costs of $1,024 and conversion of convertible notes have been retroactively restated to give effect to the recapitalization transaction. |
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) - December 31, 2020 |
|||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | (19,285 | ) | $ | (14,376 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
1,140 | 185 | ||||||
Stock-based compensation |
29,148 | 9,983 | ||||||
Loss on extinguishment of convertible notes |
107 | — | ||||||
Noncash interest expense |
5,224 | — | ||||||
Issuance of warrants |
188 | — | ||||||
Fair value adjustment of private placement warrant liability |
(4,167 | ) | — | |||||
Fair value adjustment of earnout liability |
(84,612 | ) | — | |||||
Changes in operating assets and liabilities: |
||||||||
Accounts r eceivable |
(2,614 | ) | — | |||||
Inventory |
(19,276 | ) | — | |||||
Prepaid expenses and other current assets |
(22,970 | ) | (824 | ) | ||||
Other assets |
(1,023 | ) | — | |||||
Accounts payable |
8,164 | 215 | ||||||
Accrued liabilities |
4,966 | 467 | ||||||
Related party payables |
(290 | ) | 560 | |||||
Contract liabilities |
8,684 | 2,608 | ||||||
Other liabilities |
1,425 | — | ||||||
|
|
|
|
|||||
Net cash used in |
(95,191 | ) |
(1,182 | ) | ||||
|
|
|
|
|||||
Cash Flows from Investing Activities: |
||||||||
Purchases of property and equipment |
(14,525 | ) | (431 | ) | ||||
Advanced payments for capital expenditures |
(4,257 | ) | — | |||||
Investment in equity securities |
(4,826 | ) | (122 | ) | ||||
Investment in non-consolidated affiliates |
(98 | ) | — | |||||
|
|
|
|
|||||
Net cash used in investing activities |
(23,706 | ) |
(553 | ) | ||||
|
|
|
|
|||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from issuance of common stock , net of transaction costs |
— | 18,560 | ||||||
Proceeds from Business Combination, net of redemption and transaction costs (Note 3) |
512,936 | — | ||||||
Payment f or purchase of Horizon IP |
|
|
(6,900 |
) |
|
|
— |
|
Exercise of stock options |
532 | — | ||||||
Payment of finance lease liability |
(203 | ) | (29 | ) | ||||
Debt issuance costs |
(133 | ) | — | |||||
Repurchase of warrants |
(540 | ) | — | |||||
Deferred transaction costs |
— | (137 | ) | |||||
Proceeds from issuance of convertible notes |
45,000 | 500 | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
550,692 | 18,894 | ||||||
|
|
|
|
|||||
Effect of exchange rate changes on cash |
431 | (20 | ) | |||||
|
|
|
|
|||||
Net change in cash and restricted cash |
432,226 | 17,139 | ||||||
Cash—Beginning |
17,139 | — | ||||||
|
|
|
|
|||||
Cash and restricted cash—Ending |
$ |
449,365 |
$ |
17,139 |
||||
|
|
|
|
|||||
Supplemental schedule of non-cash investing activities and financing activities: |
||||||||
Conversion of Legacy Hyzon Common Stock |
73 | — | ||||||
Recognition of earnout liability in Business Combination |
188,373 | — | ||||||
Recognition of Private Placement Warrant liability in Business Combination |
19,395 | — | ||||||
Horizon IP Agreement - Fee |
10,000 | — | ||||||
Conversion of convertible notes for common stock |
50,198 | — | ||||||
Acquisitions of property and equipment included in current liabilities |
61 | — |
Years | ||
Buildings and improvements |
30 years | |
Leasehold improvements |
5 years | |
Machinery and equipment |
7 years | |
Software |
3 - 5 years | |
Vehicles |
5 years |
Shares |
||||
Common Stock of DCRB |
20,483,179 | |||
DCRB Founders |
5,643,125 | |||
|
|
|||
Total DCRB |
26,126,304 |
|||
Conversion of Ascent options (Post-Cashless Exercise) |
6,871,667 | |||
Conversion of convertible notes |
5,022,052 | |||
PIPE shares |
35,500,000 | |||
|
|
|||
Reverse recapitalization transaction |
|
|
73,520,023 |
|
Legacy Hyzon Shares after conversion (1) |
|
|
173,474,186 |
|
Total shares of Common Stock immediately after Business Combinati on |
246,994,209 |
|||
|
|
(1) |
The number of Legacy Hyzon shares was determined from the 97,897,396 shares of Legacy Hyzon common stock outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio of 1.772. All fractional shares were rounded down. |
|
Recapitalization |
|||
Cash – DCRB trust and cash, net of redemptions and liabilities recorded by DCRB of $13.5 million |
$ | 191,181 | ||
Cash – PIPE Financing, net of transaction costs of $14.2 million |
340,797 | |||
Less: transaction costs allocated to equity |
(19,042 | ) | ||
|
|
|||
Effect of Business Combination, net of redemption and transaction costs |
$ |
512,936 |
||
|
|
|
Recapitalization |
|||
Cash – DCRB trust and cash, net of redemptions and liabilities recorded by DCRB of $13.5 million |
$ | 191,181 | ||
Cash – PIPE Financing, net of transaction costs of $14.2 million |
340,797 | |||
Conversion of convertible notes into common stock |
50,198 | |||
Recognize earnout liability |
(188,373 | ) | ||
Recognize Private Placement Warrants liability |
(19,395 | ) | ||
Recapitalization of Legacy Hyzon common shares |
83 | |||
Less: transaction costs allocated to equity |
(19,857 | ) | ||
|
|
|||
Effect of Business Combination, net of redemption and transaction costs |
$ |
354,634 |
||
|
|
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
Contract liabilities - beginning of period |
$ |
2,608 |
$ |
— |
||||
Increases net of amounts recognized as revenue during the period |
8,622 | 2,608 | ||||||
Revenue recognized, included in the contract liability balance in the beginning of the period |
— | — | ||||||
Contract liabilities - end of period |
$ |
11,230 |
$ |
2,608 |
December 31, 2021 |
December 31, 2020 |
|||||||
Raw materials |
$ | 15,727 | $ | — | ||||
Work in process |
3,518 | — | ||||||
Total inventory |
$ |
19,245 |
$ |
— |
||||
December 31, 2021 |
December 31, 2020 |
|||||||
Deposit for fuel cell components (see Note 1 7 ) |
$ | 5,008 | $ | — | ||||
Vehicle inventory deposits |
7,907 | 577 | ||||||
Production equipment deposits |
4,423 | — | ||||||
Other prepaids |
2,477 | 271 | ||||||
Prepaid insurance |
5,079 | — | ||||||
VAT receivable from government |
2,173 |
— |
||||||
VAT receivable from customers |
903 | — | ||||||
Total prepaid expenses and other current assets |
$ |
27,970 |
$ |
848 |
||||
December 31, 2021 |
December 31, 2020 |
|||||||
Land and building |
$ | 2,818 | $ | — | ||||
Machinery and equipment |
8,792 | 371 | ||||||
Software |
596 | — | ||||||
Leasehold improvements |
968 | — | ||||||
Construction in progress |
1,828 | 60 | ||||||
Total Property, plant, and equipment |
15,002 | 431 | ||||||
Less: Accumulated depreciation and amortization |
(691 | ) | (13 | ) | ||||
Property, plant and equipment, net |
$ |
14,311 |
$ |
418 |
||||
December 31, 2021 |
December 31, 2020 |
|||||||
Payroll and payroll related expenses |
$ |
2,247 |
$ |
54 |
||||
Accrued professional fees |
2,545 |
900 |
||||||
Other accrued expenses |
1,234 |
108 |
||||||
Accrued liabilities |
$ |
6,026 |
$ |
1,062 |
||||
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
US |
$ | 12,095 | $ | (13,863 | ) | |||
Non-US |
(31,380 | ) | (513 | ) | ||||
Total |
$ |
(19,285 | ) |
$ |
(14,376 | ) | ||
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
Federal tax at a statutory rate |
21.0 | % | 21.0 | % | ||||
Earnings taxed at other than Federal statutory rate |
6.8 | 0.3 | ||||||
Non-deductible interest expense |
(5.7 |
) | 0.0 |
|||||
Section 162(m) |
(25.8 |
) | 0.0 |
|||||
Change in fair value of earnout liability |
96.7 |
0.0 |
||||||
Tax basis in acquired IP |
0.3 | 0.0 | ||||||
Other |
4.6 |
0.0 |
||||||
Change in valuation allowance |
(97.9 |
) |
(21.3 |
) | ||||
Income tax provision |
0.0 |
% |
0.0 | % |
December 31, 2021 |
December 31, 2020 |
|||||||
Deferred income tax assets: |
||||||||
Net operating loss carryforward s |
$ | 18,672 | $ | 931 | ||||
Stock-based compensation |
486 | 2,097 | ||||||
Lease liabilities |
2,565 | 378 | ||||||
Tax basis in acquired IP |
2,031 |
— |
||||||
Other accrual s |
920 |
— |
||||||
Deferred income tax assets - total |
24,674 | 3,406 | ||||||
Deferred income tax liabilities: |
||||||||
Property and equipment |
(289 | ) |
(4 | ) | ||||
Right of use assets |
(2,471 | ) |
(348 | ) | ||||
Deferred income tax liabilities - total |
(2,760 | ) |
(352 | ) | ||||
Deferred income tax assets, net |
21,914 | 3,054 | ||||||
Less: Valuation allowance |
21,914 | 3,054 | ||||||
Deferred income taxes, net |
$ | — |
$ | — | ||||
December 31, 2021 |
December 31, 2020 |
|||||||
Valuation Allowances - beginning of period |
$ |
3,054 |
$ |
— |
||||
Local currency increase in reserve |
18,860 |
3,054 |
||||||
Valuation Allowances - end of period |
$ |
21,914 |
$ |
3,054 |
||||
• | Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. |
• | Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. |
• | Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. |
Fair Value Measurements on a Recurring Basis |
||||||||||||||||
Level 1 |
Level 2 |
Level 3 |
Total |
|||||||||||||
Warrant Liability – Private Placement Warrants |
$ | 15,228 |
$ | — | $ | — |
$ | 15,228 | ||||||||
Earnout shares liability |
— | — | 103,761 | 103,761 |
Assumption |
July 16, 2021 |
|||
Stock price |
$ | 10.33 | ||
Exercise price (strike price) |
$ | 11.50 | ||
Risk-free interest rate |
0.8 | % | ||
Volatility |
34.2 | % | ||
Remaining term (in years) |
5.00 |
Balance as of July 16, 2021 |
$ | 19,395 | ||
Change in estimated fair value |
(4,167 | ) | ||
|
|
|||
Balance as of December 31, 2021 |
$ |
15,228 | ||
|
|
Assumption |
December 31, 2021 |
July 16, 2021 |
||||||
Stock price |
$ | 6.49 | $ | 10.33 | ||||
Risk-free interest rate |
1.2 | % | 0.8 | % | ||||
Volatility |
90.0 | % | 90.0 | % | ||||
Remaining term (in years) |
4.54 | 5.00 |
Balance as of July 16, 2021 |
$ | 188,373 | ||
Change in estimated fair value |
(84,612 | ) | ||
|
|
|||
Balance as of December 31, 2021 |
$ |
103,761 | ||
|
|
Stock Options |
RSUs |
|||||||||||||||||||||||
Number of Options |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual (Years) |
Aggregate Intrinsic Value (in 000s) |
Number of RSUs |
Weighted Average Grant Date Fair Value |
|||||||||||||||||||
Outstanding at December 31, 2020 (1) |
19,826,031 | $ | 1.13 | — | $ | — | ||||||||||||||||||
Granted |
281,748 | $ | 1.13 | 2,799,657 | $ | 6.03 | ||||||||||||||||||
Exercised or released |
(436,037 | ) | $ | (1.22 | ) | (428,107 | ) | $ | 6.28 | |||||||||||||||
Forfeited/Cancelled |
(360,602 | ) | $ | (1.13 | ) | (518,865 | ) | $ | 5.39 | |||||||||||||||
Outstanding at December 31, 2021 |
19,311,140 | $ |
1.29 | 13.07 | 100,885 | 1,852,685 | $ |
6.14 | ||||||||||||||||
Vested and expected to vest, December 31, 2021 |
13,773,623 | $ | 1.13 | 12.69 | 74,322 | 1,852,685 | $ | 6.14 | ||||||||||||||||
Exercisable and vested at December 31, 2021 |
12,126,266 | $ | 1.13 | 13.39 | 65,013 |
(1) |
Prior period options have been adjusted to give effect to the reverse recapitalization transaction, see Note 3, Business Combination. |
2021 |
2020 |
|||||||
Expected term of options (years) |
5.0 | 0.4 to 5.0 | ||||||
Risk free interest rate |
0.79 | % | 0.1-0.4 | % | ||||
Volatility |
90 | % | 90 | % | ||||
Expected dividend |
$ | 0.00 | $ | 0.00 |
Expected volatility |
90 | % | ||||||||||
Expected dividend |
$ | 0.00 | ||||||||||
Weighted average expected term (in years) |
7.5 | |||||||||||
Risk-free rate |
68 | % |
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the “30-day redemption period”; and |
• | if, and only if, the last reported sale price of the Company’s common stock has been at least $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) on each of 20 trading days within the 30-trading day period ending on the third business day prior to the date on which the notice of redemption is given. |
• | in whole and not in part; |
• | at a price of $0.10 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption; |
• | if, and only if, the last reported sale price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) on the trading day prior to the date on which the notice of redemption is given; and |
• | if the last sale price of the Company’s common stock on the trading day prior to the date on which the notice of redemption is given is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants. |
Year Ended December 31, |
For the period January 21, 2020 (Inception) – December 31, |
|||||||
2021 |
2020 |
|||||||
Ne t loss attributable to Hyzon |
$ | (13,846 | ) | $ | (14,271 | ) | ||
Weighted average shares outstanding: |
||||||||
Basic |
203,897 | 152,650 | ||||||
Effect of dilutive securities |
— | — | ||||||
|
|
|
|
|||||
Diluted |
203,897 | 152,650 | ||||||
Net loss per share attributable to Hyzon: |
||||||||
Basic |
$ |
(0.07 | ) | $ | (0.09 | ) | ||
Diluted |
$ |
(0.07 | ) | $ | (0.09 | ) |
Year Ended December 31, |
For the Period January 21, 2020 (Inception) – December 31, |
|||||||
2021 |
2020 |
|||||||
Restricted stock units |
1,853 |
— |
||||||
Stock options with service conditions |
12,296 | 14,288 |
||||||
Stock options for former CTO |
|
|
1,477 |
|
|
|
— |
|
Stock options with market and performance conditions |
5,538 | 5,538 | ||||||
Private placement warrants |
8,015 | — | ||||||
Public w arrants |
11,286 | — | ||||||
Earnout shares |
23,250 | — | ||||||
Hongyun warrants |
31 |
— |
||||||
Ardour warrants |
293 |
— |
December 31, 2021 |
December 31, 2020 |
|||||||
Operating leases: |
||||||||
Operating lease right-of-use assets |
$ | 9,933 | $ | 943 | ||||
Operating lease liabilities |
$ | (10,062 | ) | $ | (942 | ) | ||
Finance leases: |
||||||||
s |
$ | 332 | $ | 713 | ||||
Finance lease liabilities |
$ | (654 | ) | $ | (857 | ) | ||
Weighted average remaining lease term: |
||||||||
Operating leases |
7.3 years | 4.9 years | ||||||
Finance leases |
1.4 years | 2.4 years | ||||||
Weighted average discount rate: |
||||||||
Operating leases |
5.7 | % |
7.1 | % | ||||
Finance leases |
7.0 | % |
6.9 | % |
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) – December 31, 2020 |
|||||||
Operating lease cost |
$ |
862 | $ | 19 | ||||
Variable lease cost |
205 | 30 | ||||||
Finance lease cost: |
||||||||
Amortization of right-of-use assets |
381 | 172 | ||||||
Interest on lease liabilities |
53 | 35 | ||||||
|
|
|
|
|||||
Total lease cost |
$ |
1,501 | $ |
256 | ||||
|
|
|
|
Year Ended December 31, 2021 |
For the period January 21, 2020 (Inception) - December 31, 2020 |
|||||||
Cash paid for amount included in the measurement of lease liabilities: |
||||||||
Operating cash flows from operating leases |
$ |
739 | $ | 19 | ||||
Operating cash flows from finance leases |
$ |
53 | $ | 35 | ||||
Financing cash flows from finance leases |
$ |
203 | $ | 29 | ||||
Right-of-use assets obtained in exchange for new lease liabilities: |
||||||||
Operating leases |
$ |
9,588 | $ | 780 | ||||
Finance leases |
$ |
— | $ | 886 |
As of December 31, 2021 |
||||||||
Operating Leases |
Finance Leases |
|||||||
2022 |
$ |
1,978 | $ |
448 | ||||
2023 |
1,894 | 240 | ||||||
2024 |
1,806 | — | ||||||
2025 |
1,745 | — | ||||||
2026 and thereafter |
4,737 | — | ||||||
|
|
|
|
|||||
Total minimum lease payments |
12,160 | 688 | ||||||
Less: imputed interest |
2,098 | 34 | ||||||
|
|
|
|
|||||
Present value of lease obligations |
10,062 | 654 | ||||||
n |
1,453 | 433 | ||||||
|
|
|
|
|||||
s |
$ |
8,609 | $ |
221 | ||||
|
|
|
|
(i) | hiring additional finance and accounting personnel over time to augment our accounting staff and to provide more resources for complex accounting matters and financial reporting; |
(ii) | further developing and implementing formal policies, processes and documentation procedures relating to our financial reporting and consulting with accounting experts; |
(iii) | engaging with external consultants with public company and technical accounting experience to facilitate accurate and timely accounting closes and to accurately prepare and review the consolidated financial statements and related footnote disclosures. We plan to retain these financial consultants, as needed, until such time that the required financial controls have been fully implemented; and |
(iv) | adopting new technological solutions. |
Name |
Age |
Position | ||||
Executive Officers |
||||||
George Gu |
51 | Executive Chairman | ||||
Craig Knight |
53 | Director and Chief Executive Officer | ||||
Mark Gordon |
51 | Director and Chief Financial Officer | ||||
Shinichi Hirano |
62 | Chief Technology Officer | ||||
John Zavoli |
62 | General Counsel & Chief Legal Officer | ||||
Parker Meeks |
40 | Chief Strategy Officer | ||||
Pat Griffin |
57 | President of Vehicle Operations | ||||
Non-Employee Directors |
||||||
Erik Anderson (2) |
62 | Director | ||||
Ivy Brown (1) |
58 | Director | ||||
Dennis Edwards (2)(3) |
50 | Director | ||||
Viktor Meng (2)(3) |
46 | Director | ||||
Ki Deok Park (1) |
52 | Director | ||||
Elaine Wong (1)(3) |
46 | Director; Lead Independent Director |
(1) | Member of the audit committee. |
(2) | Member of the compensation committee. |
(3) | Member of the nominating and corporate governance committee. |
• | the Board to have a majority of independent directors; |
• | that Hyzon establish a compensation committee comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
• | that Hyzon have independent director oversight of Hyzon’s director nominations. |
• | evaluating the performance, independence and qualifications of our independent auditors and determining their compensation and whether to retain our existing independent auditors or engage new independent auditors; |
• | reviewing our financial reporting processes and disclosure controls; |
• | reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services; |
• | reviewing with the independent auditors the annual audit plan, including the scope of audit activities and all critical accounting policies and estimates to be used by us; |
• | obtaining and reviewing at least annually a report by our independent auditors describing the independent auditors’ internal quality control procedures and any material issues raised by the most recent internal quality-control review; |
• | monitoring the rotation of partners of our independent auditors on our engagement team as required by law; |
• | prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor; |
• | preparing any report of the audit committee required by the rules and regulations of the SEC for inclusion in our annual proxy statement and reviewing our annual and quarterly financial statements and reports, including the disclosures contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and discussing the statements and reports with our independent auditors and management; |
• | reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy, and effectiveness of our financial controls and critical accounting policies and estimates; |
• | reviewing with management and our auditors any earnings announcements and other public announcements regarding material developments; |
• | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters and for the confidential, anonymous submission by our employees or any provider of accounting-related services of concerns regarding questionable accounting and auditing matters and review of submissions and the treatment of any such complaints; |
• | reviewing and approving of any related party transactions that are required to be disclosed under SEC rules that require such approval under our related party transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of ethics; |
• | reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; |
• | conducting and reviewing with the Board an annual self-assessment of the performance of the audit committee, and reviewing and assessing the audit committee charter at least annually; and |
• | reporting to the Board on a regular basis. |
• | establishing our general compensation philosophy and, in consultation with management, overseeing the development and implementation of compensation programs; |
• | reviewing and approving the corporate objectives that pertain to the determination of executive compensation; |
• | determining and approving the compensation and other terms of employment of our executive officers; |
• | reviewing and approving performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; |
• | making recommendations to the Board regarding the adoption or amendment of equity and cash incentive plans and approving such plans or amendments thereto to the extent authorized by the Board; |
• | overseeing the activities of the committee or committees administering our retirement and benefit plans; |
• | reviewing and making recommendations to the Board regarding the type and amount of compensation to be paid or awarded to non-employee board members; |
• | reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act; |
• | administering our equity incentive plans, to the extent such authority is delegated by the Board; |
• | reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections, indemnification agreements and any other material agreements for our executive officers; |
• | reviewing with management our disclosures under the caption “Compensation Discussion and Analysis” in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is required to be included in any such report or proxy statement; |
• | preparing an annual report on executive compensation, to the extent such report is required to be included in our annual proxy statement or Form 10-K; |
• | reviewing and evaluating on an annual basis the performance of the compensation committee and recommending such changes as deemed necessary with the Board; and |
• | in consultation with management, overseeing regulatory compliance with respect to compensation matters including overseeing our policies on structuring compensation programs to preserve tax deductibility. |
• | identifying, reviewing and making recommendations of candidates to serve on the Board; |
• | evaluating the performance of the Board, committees of the Board and individual directors and determining whether continued service on the Board is appropriate; |
• | evaluating nominations by stockholders and management of candidates for election to the Board; |
• | evaluating the current size, composition and organization of the Board and its committees and making recommendations to the Board for approvals; |
• | evaluating the “independence” of directors and director nominees against the independence requirements under the NASDAQ Rules and regulations promulgated by the SEC and such other qualifications as may be established by the Board from time to time and make recommendations to the Board as to the independence of directors and nominees; |
• | recommending to the Board directors to serve as members of each committee, as well as candidates to fill vacancies on any committee of the Board; |
• | reviewing annually our corporate governance policies and principles and recommending to the Board any changes to such policies and principles; |
• | advising and making recommendations to the Board on corporate governance matters; and |
• | reviewing annually the nominating and corporate governance committee charter and recommending any proposed changes to the Board, including undertaking an annual review of its own performance. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or its stockholders. |
• | George Gu, Executive Chairman; |
• | Craig Knight, Chief Executive Officer; |
• | Parker Meeks, Chief Strategy Officer; and |
• | Gary Robb, Former Chief Technology Officer |
Name and Position |
Year |
Salary ($) (A) |
Bonus ($) |
Option Awards ($) (B) |
Stock Awards ($) (C) |
All Other Compensation ($) (D) |
Total ($) |
|||||||||||||||||||||
George Gu Executive Chairman |
|
2021 2020 |
|
|
410,577 211,591 |
|
|
— — |
|
|
— 6,140,625 |
|
|
— — |
|
|
18,942 5,493 |
|
|
429,519 6,357,709 |
| |||||||
Craig Knight Chief Executive Officer |
|
2021 2020 |
|
|
378,658 148,090 |
|
|
— — |
|
|
— 4,492,188 |
|
|
— — |
|
|
35,757 — |
|
|
414,415 4,640,278 |
| |||||||
Parker Meeks Chief Strategy Officer (1) |
2021 | 250,961 | — | — | 2,603,997 | 11,133 | 2,866,091 | |||||||||||||||||||||
Gary Robb Former Chief Technology Officer |
|
2021 2020 |
|
|
151,038 120,000 |
|
|
— 7,500 |
|
|
— 1,378,000 |
|
|
2,535,000 — |
|
|
111,530 6,494 |
|
|
2,797,568 1,511,994 |
|
(1) | Parker Meeks became a Named Executive Officer of Hyzon for the first time in 2021. |
(A) |
Base Salary |
(B) |
Option Awards |
(C) |
Stock Awards |
(D) |
All Other Compensation |
Option Awards |
Stock Awards |
|||||||||||||||||||||||||||||
Name |
Award Type |
Grant Date |
Number of Securities Underlying Unexercised Options - Exercisable (#) |
Number of Securities Underlying Unexercised Options - Unexercisable (#) |
Option Exercise Price ($) |
Option Expiration Date |
Number of Shares or Units of Stock that Have Not Vested (#) |
Market Value of Shares or Units of Stock that Have Not Vested (5) ($) |
||||||||||||||||||||||
Craig Knight (1) |
Options | 11/12/2020 | 5,537,500 | — | 1.13 | 1/4/2036 | — | — | ||||||||||||||||||||||
George Gu (2) |
Options | 11/12/2020 | 5,537,500 | 5,537,500 | 1.41 | 1/3/2036 | — | — | ||||||||||||||||||||||
Parker Meeks (3) |
RSUs | 6/9/2021 | — | — | — | — | 372,120 | |
2,415,059 |
| ||||||||||||||||||||
Gary Robb (4) |
Options | 11/12/2020 | 590,666 | 1,181,334 | 1.13 | 11/11/2030 | — | — | ||||||||||||||||||||||
RSUs | — | — | — | — | — | 125,000 | 811,250 |
(1) | The option awards reported in these columns granted to Mr. Knight were fully vested on the grant date. |
(2) | The option awards reported in this column granted to Mr. Gu vest as follows: 50% on the grant date and 50% on the occurrence of a Qualified HFCT Exit Event (as defined therein and described below under “Additional Narrative Disclosure—Potential Payments Upon a Termination or Change in Control”). |
(3) | The RSUs granted to Mr. Meeks vest in four equal annual installments commencing upon the grant date, subject to continued employment. |
(4) | The option awards granted to Mr. Robb on November 20, 2020 will vest in six equal tranches over first years beginning on the grant date such that two tranches are currently vested and exercisable. The 125,000 RSUs reported for Mr. Robb will vest on September 17, 2022. |
(5) | Market value is calculated by multiplying the closing market price of $6.49 for Hyzon common stock, as reported by NASDAQ, by the number of shares or units of stock. |
• | An annual retainer of $60,000; |
• | An annual retainer of $20,000 for the chair of the Audit Committee, $15,000 for the chair of the Compensation Committee and $10,000 for the chair of the Nominating and Corporate Governance Committee; |
• | An annual retainer of $10,000 for members of the Audit Committee, $7,500 for members of the Compensation Committee and $5,000 for members of the Nominating and Corporate Governance Committee; |
• | An initial equity retainer with a value of $225,000 (payable in the form of stock options and restricted stock units, granted in connection with initial election to the Board); |
• | An annual equity retainer with a value of $165,000 in connection with the annual shareholders meeting, split equally between non-qualified stock options and restricted stock units, that vests on the one-year anniversary of the grant; and |
• | An additional annual cash retainer of $30,000 for serving as Lead Director. |
2021 |
Fees Earned or Paid in Cash (1) ($) |
Stock Awards (2) ($) |
Option Awards (2) ($) |
Total ($) |
||||||||||||
Erik Anderson |
37,500 | — | — | 37,500 | ||||||||||||
Ivy Brown |
40,000 | — | — | 40,000 | ||||||||||||
Dennis Edwards |
35,000 | — | — | 35,000 | ||||||||||||
Viktor Meng |
35,000 | — | — | 35,000 | ||||||||||||
Ki Deok Park |
35,000 | — | — | 35,000 | ||||||||||||
Elaine Wong |
70,000 | — | — | 70,000 |
(1) | Amounts reflected a pro-rated annual cash retainer of $30,000 in 2021 for all directors. Fees for service as a committee member and committee chair in 2021 were also prorated. |
(2) | No stock or option awards were granted in 2021. |
• | each person known to the Company to be the beneficial owner of more than 5% of outstanding Class A Common Stock; |
• | each of the Company’s named executive officers and directors; and |
• | all executive officers and directors of the Company as a group. |
Name and Address of Beneficial Owners |
Number of Shares of Class A Common Stock Beneficially Owned |
% of Outstanding Class A Common Stock |
||||||
Five Percent Holders (1) |
155,639,006 | 62.8 | % | |||||
Horizon Fuel Cell Technologies Pte. Ltd. (2) |
||||||||
Directors and Executive Officers |
||||||||
Erik Anderson (3) |
630,947 | * | ||||||
Ivy Brown |
— | * | ||||||
Dennis Edwards |
177,200 | * | ||||||
Viktor Meng (4) |
44,300 | * | ||||||
Ki Deok Park |
— | * | ||||||
Elaine Wong |
781,386 | * | ||||||
Mark Gordon |
2,735,984 | 1.1 | % | |||||
George Gu (5) |
5,759,000 | 2.3 | % | |||||
Craig Knight (6) |
5,880,700 | 2.3 | % | |||||
Parker Meeks |
89,404 | * | ||||||
Gary Robb ( 7) |
1,010,999 | * | ||||||
All Directors and Executive Officers as a group (14 persons, including the foregoing) (8) |
17,146,661 | 6.6 | % |
* | Less than one percent. |
(1) | The Company is permitted to rely on the information reported by each beneficial owner in filings with the SEC and has no reason to believe that the information is incomplete or inaccurate or that the beneficial owner should have filed an amended report and did not. |
(2) | Hymas is the record holder of the shares. Hymas is 79.62% owned indirectly by Horizon, through its subsidiaries, including JS Horizon and Horizon Fuel Cell Technology (Hong Kong) Ltd. (“HFCT HK”). Horizon, by reason of its ownership of the voting securities of JS Horizon, JS Horizon’s ownership of the voting securities of HFCT HK, and HFCT HK’s ownership of the voting securities of Hymas, ultimately has the right to elect or appoint the members of the governing body of Hymas and, therefore, to direct the management and policies of Hymas. As a result, Horizon has voting and investment power over the shares of Class A Common Stock held of record by Hymas. Mr. Gu beneficially owns 17.6% of Horizon, consisting of 119,892 Ordinary Shares of Horizon, which is approximately 46.9% of the outstanding Ordinary Shares of Horizon, and 1 D-1 Preferred Share of Horizon, which is approximately 0.0% of the outstanding D-1 Preferred Shares of Horizon. Mr. Knight beneficially 2.4% of Horizon, consisting of 1,205 Ordinary Shares of Horizon, which is approximately 0.5% of the outstanding Ordinary Shares of Horizon, and 15,257 shares of A Preferred Shares of Horizon, which is approximately 19.9% of the outstanding A Preferred Shares of Horizon. Mr. Gu and Mr. Knight disclaim any beneficial ownership of Class A Common Stock by reason of their beneficial ownership of shares of Horizon. The address for Horizon and Hymas is Enterprise Hub, 48 Toh Guan Road East, Postal 608586, #05-124, Singapore. The address for JS Horizon is 302-309BOT Building A, New Environmental Materials Industrial Park, Huada Road, Jingang Town, Zhangjiagang City, Jiangsu, China. The address for HFCT HK is 11/F., Capital Centre, 151 Gloucester Road, Wanchai, Hong Kong. |
(3) | WRG DCRB Investors, LLC is the record holder of the shares reported herein. WestRiver Management, LLC is the managing member of WRG DCRB Investors, LLC. Erik Anderson is the sole member of WestRiver Management, LLC and has voting and investment discretion with respect to the common stock held of record by WRG DCRB Investors, LLC. As such, each of WestRiver Management, LLC and Erik Anderson may be deemed to have or share beneficial ownership of the Class A Common Stock held directly by WRG. Each such entity or person disclaims any such beneficial ownership. The business address of each of these entities and Erik Anderson is 920 5th Ave, Ste 3450, Seattle, WA 98104. |
(4) | Consists of 26,580 shares of Class A Common Stock, and 17,720 shares of Class A Common Stock issuable upon the exercise of options within 60 days. |
(5) | Consists of 221,500 shares of Class A Common Stock, and 5,537,500 shares of Class A Common Stock issuable upon the exercise of options within 60 days. |
(6) | Consists of 343,200 shares of Class A Common Stock, and 5,537,500 shares of Class A Common Stock issuable upon the exercise of options within 60 days. |
(7) | Consists of 125,000 shares of Class A Common Stock, and 885,999 shares of Class A Common Stock issuable upon the exercise of options or restricted stock units within 60 days. |
(8) | Consists of 5,167,942 shares of Class A Common Stock and 11,978,719 shares of Class A Common Stock issuable upon the exercise of options or restricted stock units within 60 days. |
• | The DCRB Founders Warrant Parties shall not, with respect to an aggregate of 4,885,875 private placement warrants (or shares of Class A Common Stock issued upon exercise of private placement warrants), (a)(i) sell or assign, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of, (ii) agree to dispose of, directly or indirectly, or (iii) establish or increase a “put equivalent position” or liquidation with respect to or decrease of a “call equivalent position” within the meaning of Section 16 of the Exchange Act and the rules and regulations of the SEC promulgated thereunder with respect to, in each case (i), (ii) and (iii), any security, (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) publicly announce any intention to effect any transaction specified in clause (a) or (b), until the earlier of (i) one year after the Closing and |
(ii) subsequent to the Closing, (x) the date on which the last sale price of the Class A Common Stock quoted on NASDAQ (or the exchange on which the shares of DCRB Class A Common Stock are then listed) equals or exceeds $11.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period or (y) the date on which DCRB completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in the holders of DCRB Class A Common Stock having the right to exchange their shares of Class A Common Stock for cash, securities or other property; |
• | Upon and subject to the Closing, an aggregate of 814,313 private placement warrants (the “$12.00 Warrants”) became subject to potential forfeiture, and each DCRB Founders Warrant Party agreed not to exercise such $12.00 Warrants, unless and until a $12.00 Triggering Event (as defined below) occurs. Prior to the occurrence of a $12.00 Triggering Event, each DCRB Founders Warrant Party shall not Transfer any of the $12.00 Warrants. In the event no $12.00 Triggering Event occurs during the five year period commencing on the one year anniversary of the Closing (the “Earnout Period”), the $12.00 Warrants shall immediately be forfeited to Hyzon for no consideration as a contribution to the capital of Hyzon and immediately cancelled. “$12.00 Triggering Event” means the occurrence of a date on which the last reported sales price of one share of Class A Common Stock quoted on NASDAQ (or the exchange on which the shares of Class A Common Stock are then listed) is greater than or equal to $12.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading day period within the Earnout Period; provided, that, if, during the Earnout Period, there is a change of control pursuant to which the holders of Class A Common Stock have the right to receive consideration implying a value of Class A Common Stock (as determined in good faith by the Board) of (i) less than $12.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), then the $12.00 Warrants shall immediately be forfeited to us for no consideration and immediately cancelled; or (ii) greater than or equal to $12.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), then the $12.00 Triggering Event shall be deemed to have occurred. |
• | Upon and subject to the Closing, an aggregate of 814,312 private placement warrants (the “$14.00 Warrants”) became subject to potential forfeiture, and each DCRB Founders Warrant Party agreed not to exercise such $14.00 Warrants, unless and until a $14.00 Triggering Event (as defined below) occurs. Prior to the occurrence of a $14.00 Triggering Event, each DCRB Founders Warrant Party shall not transfer any of the $14.00 Warrants. In the event no $14.00 Triggering Event occurs during the Earnout Period, the $14.00 Warrants shall immediately be forfeited to Hyzon for no consideration as a contribution to the capital of Hyzon and immediately cancelled. “$14.00 Triggering Event” means the occurrence of a date on which the last reported sales price of one share of Class A Common Stock quoted on NASDAQ (or the exchange on which the shares of Class A Common Stock are then listed) is greater than or equal to $14.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 consecutive trading day period within the Earnout Period; provided, that, if, during the Earnout Period, there is a change of control pursuant to which the holders of Class A Common Stock have the right to receive consideration implying a value of Class A Common Stock (as determined in good faith by the Board) (i) less than $14.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), then the $14.00 Warrants shall immediately be forfeited to us for no consideration and immediately cancelled; or (ii) of greater than or equal to $14.00 (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), then the $14.00 Triggering Event shall be deemed to have occurred. |
2021 |
2020 |
|||||||
Audit Fees (1) |
$ | 1,441,326 | $ | 1,022,048 | ||||
Audit-Related Fees (2) |
73,465 | 137,952 | ||||||
Tax (3) |
93,000 | — | ||||||
All Other Fees (4) |
— | — | ||||||
|
|
|
|
|||||
Total |
$ |
1,607,791 |
$ |
1,160,000 |
||||
|
|
|
|
(1) |
Audit Fees |
(2) |
Audit-Related Fees |
(3) |
Tax Fees |
(4) |
All Other Fees |
2021 |
2020 |
|||||||
Audit Fees (1) |
$ | 85,125 | $ | 91,820 | ||||
Audit-Related Fees (2) |
— | — | ||||||
Tax (3) |
5,000 | 5,000 | ||||||
All Other Fees (4) |
— | — | ||||||
|
|
|
|
|||||
Total |
$ |
90,125 |
$ |
96,820 |
||||
|
|
|
|
(1) |
Audit Fees 10-Q, the audit of our December 31, 2020 financial statements included in the Original Filing and the audit of our restated financial statements included in this Amendment, and services that are normally provided by our independent registered public accounting firm in connection with statutory and regulatory filings or engagements. |
(2) |
Audit-Related Fees |
(3) |
Tax Fees |
(4) |
All Other Fees |
1. | Financial Statements: The information concerning the consolidated financial statements and Report of Independent Registered Public Accounting Firm required by this Item is incorporated by reference herein to the section of this Annual Report on Form 10-K in Item 8, titled “Financial Statements and Supplementary Data.” |
2. | Financial Statement Schedules: No schedules are required |
Exhibit No. |
Exhibit | |
32.1* | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2022. | |
32.2* | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2022. | |
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104.1* | Cover Page Interactive Data File (embedded within the Inline XBRL) |
† | All schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |
* | Filed or furnished herewith. |
# | Indicates management contract or compensatory arrangement. |
HYZON MOTORS INC. | ||||||
Date: March 30, 2022 | /s/ Craig Knight | |||||
Craig Knight Chief Executive Officer |
Name |
Title |
Date | ||
/s Craig Knight |
Chief Executive Officer and Director | March 30, 2022 | ||
Craig Knight | (Principal Executive Officer) | |||
/s/ Mark Gordon |
Chief Financial Officer and Director | March 30, 2022 | ||
Mark Gordon | (Principal Financial Officer) | |||
/s/ Jiajia Wu |
Chief Accounting Officer | March 30, 2022 | ||
Jiajia Wu | (Principal Accounting Officer) | |||
/s/ George Gu |
Executive Chairman | March 30, 2022 | ||
George Gu | ||||
/s/ Erik Anderson |
Director | March 30, 2022 | ||
Erik Anderson | ||||
/s/ Ivy Brown |
Director | March 30, 2022 | ||
Ivy Brown | ||||
/s/ Dennis Edwards |
Director | March 30, 2022 | ||
Dennis Edwards | ||||
/s/ Viktor Meng |
Director | March 30, 2022 | ||
Viktor Meng | ||||
/s/ Ki Deok Park |
Director | March 30, 2022 | ||
Ki Deok Park | ||||
/s/ Elaine Wong |
Director | March 30, 2022 | ||
Elaine Wong |
Exhibit 4.5
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
AS OF DECEMBER 31, 2021
As of December 31, 2021, we had two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our Class A Common Stock and our public warrants. The following is a summary of the material terms of these securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our second amended and restated certificate of incorporation (the Charter), the second amended and restated bylaws (the Bylaws) and the warrant-related documents described herein, which are exhibits to the Annual Report on Form 10-K of which this exhibit is a part. We urge to you read each of the Charter, the Bylaws and the warrant-related documents described herein in their entirety for a complete description of the rights and preferences of our securities.
Common Stock
The Certificate of Incorporation authorizes the issuance of 410,000,000 shares of capital stock, par value of $0.0001 per share, consisting of (a) 400,000,000 shares of Class A Common Stock and (b) 10,000,000 shares of preferred stock.
Class A Common Stock
Voting Power
Except as otherwise required by law, the Charter or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of Class A Common Stock possess all voting power for the election of directors and all other matters requiring stockholder action. Holders of Class A Common Stock are entitled to one vote per share on matters to be voted on by stockholders.
Director Elections
Under the Charter, our Board of Directors (the Board) is divided into three classes, each of which generally serves for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors.
Dividend Rights
Subject to applicable law and the rights, if any, of holders of outstanding preferred stock, holders of Class A Common Stock are entitled to receive such dividends and other distributions (payable in cash, property or capital stock) when, as and if declared thereon by the Board from time to time out of any assets or funds legally available therefor, and will share equally on a per share basis in such dividends and distributions.
Liquidation, Dissolution and Winding Up
Subject to applicable law and the rights, if any, of holders of outstanding preferred stock, in the event of voluntary or involuntary liquidation, dissolution or winding-up, after payment or provision for payment of the debts and other liabilities of Hyzon, the holders of Class A Common Stock will be entitled to receive all the remaining assets of Hyzon available for distribution to its stockholders, ratably in proportion to the number of shares of Class A Common Stock held by them.
Preferred Stock
The Charter provides that shares of preferred stock may be issued from time to time in one or more series. The Board is authorized to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other rights, if any, of each such series and any qualifications, limitations and restrictions thereof, applicable to the shares of each series.
1
The Board is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the Class A Common Stock and could have antitakeover effects. The ability of the Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Hyzon or the removal of Hyzons management. Hyzon has no Preferred Stock outstanding as of the date hereof.
Warrants
Public Stockholders Warrants
Each whole warrant entitles the registered holder to purchase one whole share of our Class A Common Stock at a price of $11.50 per share, subject to adjustment as discussed below, Pursuant to the Warrant Agreement (as defined below), a warrant holder may exercise its warrants only for a whole number of shares of Class A Common Stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. The warrants will expire on July 16, 2026, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
We will not be obligated to deliver any shares of Class A Common Stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act of 1933, as amended (the Securities Act) with respect to the shares of Class A Common Stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant will be exercisable and we will not be obligated to issue shares of Class A Common Stock upon exercise of a warrant unless the Class A Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class A Common Stock underlying such unit.
We have agreed to use our best efforts to maintain the effectiveness of a registration statement for the registration, under the Securities Act, of the shares of Class A Common Stock issuable upon exercise of the warrants and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the Warrant Agreement.
Notwithstanding the above, if our Class A Common Stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a covered security under Section 18(b)(1) of the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a cashless basis in accordance with Section 3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, but we will be required to use our best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Redemption of Warrants for Cash When the Price Per Share of Class A Common Stock Equals or Exceeds $18.00
Once the warrants become exercisable, we may call the warrants for redemption (except as described below with respect to the private placement warrants):
| in whole and not in part; |
| at a price of $0.01 per warrant; |
| upon not less than 30 days prior written notice of redemption (the 30-day redemption period) to each warrant holder; and |
| if, and only if, the reported last sale price of the Class A Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrant holders. |
2
We will not redeem the warrants for cash unless a registration statement under the Securities Act covering the shares of Class A Common Stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A Common Stock is available throughout the 30-day redemption period. Any such exercise would not be on a cashless basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A Common Stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.
Redemption of Warrants for Cash When the Price Per Share of Class A Common Stock Equals or Exceeds $10.00
Once the warrants become exercisable, we may call the warrants for redemption (except as described below with respect to the private placement warrants):
| in whole and not in part; |
| at a price of $0.01 per warrant, provided that holders will be able to exercise their warrants prior to redemption and receive that number of shares of Class A Common Stock determined by reference to the table below, based on the redemption date and the fair market value of our Class A Common Stock (as defined below) except as otherwise described below); |
| upon a minimum of 30 days prior written notice; |
| if, and only if, the last sale price of our Class A Common Stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading prior to the date on which we send the notice of redemption to the warrant holders; and |
| if the last sale price of our Class A Common Stock on the day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above. |
Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants on a cashless basis. The numbers in the table below represent the number of shares of Class A Common Stock that a warrant holder will receive upon a cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the fair market value of our Class A Common Stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the table below.
Redemption Date | Fair Market Value of Class A Common Stock | |||||||||||||||||||||||||||||||||||
(period to expiration of warrants) | ≤10.00 | 11.00 | 12.00 | 13.00 | 14.00 | 15.00 | 16.00 | 17.00 | ≥18.00 | |||||||||||||||||||||||||||
60 months |
0.261 | 0.281 | 0.297 | 0.311 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
57 months |
0.257 | 0.277 | 0.294 | 0.310 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
54 months |
0.252 | 0.272 | 0.291 | 0.307 | 0.322 | 0.335 | 0.347 | 0.357 | 0.361 | |||||||||||||||||||||||||||
51 months |
0.246 | 0.268 | 0.287 | 0.304 | 0.320 | 0.333 | 0.346 | 0.357 | 0.361 | |||||||||||||||||||||||||||
48 months |
0.241 | 0.263 | 0.283 | 0.301 | 0.317 | 0.332 | 0.344 | 0.356 | 0.361 | |||||||||||||||||||||||||||
45 months |
0.235 | 0.258 | 0.279 | 0.298 | 0.315 | 0.330 | 0.343 | 0.356 | 0.361 | |||||||||||||||||||||||||||
42 months |
0.228 | 0.252 | 0.274 | 0.294 | 0.312 | 0.328 | 0.342 | 0.355 | 0.361 | |||||||||||||||||||||||||||
39 months |
0.221 | 0.246 | 0.269 | 0.290 | 0.309 | 0.325 | 0.340 | 0.354 | 0.361 | |||||||||||||||||||||||||||
36 months |
0.213 | 0.239 | 0.263 | 0.285 | 0.305 | 0.323 | 0.339 | 0.353 | 0.361 | |||||||||||||||||||||||||||
33 months |
0.205 | 0.232 | 0.257 | 0.280 | 0.301 | 0.320 | 0.337 | 0.352 | 0.361 | |||||||||||||||||||||||||||
30 months |
0.196 | 0.224 | 0.250 | 0.274 | 0.297 | 0.316 | 0.335 | 0.351 | 0.361 | |||||||||||||||||||||||||||
27 months |
0.185 | 0.214 | 0.242 | 0.268 | 0.291 | 0.313 | 0.332 | 0.350 | 0.361 | |||||||||||||||||||||||||||
24 months |
0.173 | 0.204 | 0.233 | 0.260 | 0.285 | 0.308 | 0.329 | 0.348 | 0.361 | |||||||||||||||||||||||||||
21 months |
0.161 | 0.193 | 0.223 | 0.252 | 0.279 | 0.304 | 0.326 | 0.347 | 0.361 | |||||||||||||||||||||||||||
18 months |
0.146 | 0.179 | 0.211 | 0.242 | 0.271 | 0.298 | 0.322 | 0.345 | 0.361 | |||||||||||||||||||||||||||
15 months |
0.130 | 0.164 | 0.197 | 0.230 | 0.262 | 0.291 | 0.317 | 0.342 | 0.361 | |||||||||||||||||||||||||||
12 months |
0.111 | 0.146 | 0.181 | 0.216 | 0.250 | 0.282 | 0.312 | 0.339 | 0.361 | |||||||||||||||||||||||||||
9 months |
0.090 | 0.125 | 0.162 | 0.199 | 0.237 | 0.272 | 0.305 | 0.336 | 0.361 | |||||||||||||||||||||||||||
6 months |
0.065 | 0.099 | 0.137 | 0.178 | 0.219 | 0.259 | 0.296 | 0.331 | 0.361 | |||||||||||||||||||||||||||
3 months |
0.034 | 0.065 | 0.104 | 0.150 | 0.197 | 0.243 | 0.286 | 0.326 | 0.361 | |||||||||||||||||||||||||||
0 months |
| | 0.042 | 0.115 | 0.179 | 0.233 | 0.281 | 0.323 | 0.361 |
3
The fair market value of our Class A Common Stock shall mean the average reported last sale price of our Class A Common Stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. We will provide our warrant holders with the final fair market value no later than one business day after the ten-trading day period described above ends.
The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of shares of Class A Common Stock to be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365-day year. For example, if the average reported last sale price of our Class A Common Stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.277 shares of Class A Common Stock for each whole warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the average reported last sale price of our Class A Common Stock for the 10 trading days ending on the third trading date prior to the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.298 shares of Class A Common Stock for each whole warrant. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class A Common Stock per whole warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money (i.e. the trading price of our Class A Common Stock is below the exercise price of the warrants) and about to expire, they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of Class A Common Stock.
This redemption feature differs from the typical warrant redemption features used in some other blank check offerings, which typically only provide for a redemption of warrants for cash (other than the private placement warrants) when the trading price for the Class A Common Stock exceeds $18.00 per share for a specified period of time. This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the Class A Common Stock is trading at or above $10.00 per share, which may be at a time when the trading price of our Class A Common Stock is below the exercise price of the warrants. We have established this redemption feature to provide the warrants with an additional liquidity feature, which provides us with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold. Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants, based on the redemption price as determined pursuant to the above table. We have calculated the redemption prices as set forth in the table above to reflect a Black-Scholes option pricing model with a fixed volatility input as of October 21, 2020. This redemption right provides us an additional mechanism by which to redeem all of the outstanding warrants and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have been exercised or redeemed, and we will effectively be required to pay the redemption price to warrant holders if we choose to exercise this redemption right, it will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders.
4
As stated above, we can redeem the warrants when the Class A Common Stock is trading at a price starting at $10.00, which is below the exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares of Class A Common Stock. If we choose to redeem the warrants when the Class A Common Stock is trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer shares of Class A Common Stock than they would have received if they had chosen to wait to exercise their warrants for shares of Class A Common Stock if and when such shares of Class A Common Stock were trading at a price higher than the exercise price of $11.50. No fractional shares of Class A Common Stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest whole number of the number of shares of Class A Common Stock to be issued to the holder.
Redemption Procedures
A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such persons affiliates), to the warrant agents actual knowledge, would beneficially own in excess 9.8% (or such other amount as a holder may specify) of the shares of Class A Common Stock outstanding immediately after giving effect to such exercise.
Anti-Dilution Adjustments
The stock prices set forth in the column headings of the table above shall be adjusted as of any date on which the number of shares issuable upon exercise of a warrant is adjusted pursuant to the following three paragraphs. The adjusted stock prices in the column headings shall equal the stock prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a warrant as so adjusted. The number of shares in the table above shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant.
If the number of outstanding shares of Class A Common Stock is increased by a stock dividend payable in shares of Class A Common Stock, or by a split-up of shares of Class A Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of Class A Common Stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares of Class A Common Stock. A rights offering to holders of Class A Common Stock entitling holders to purchase shares of Class A Common Stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Class A Common Stock equal to the product of (i) the number of shares of Class A Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A Common Stock) multiplied by (ii) 1 minus the quotient of (x) the price per share of Class A Common Stock paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Class A Common Stock, in determining the price payable for Class A Common Stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of Class A Common Stock as reported during the 10 trading day period ending on the trading day prior to the first date on which the shares of Class A Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.
In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Class A Common Stock on account of such shares of Class A Common Stock (or other shares of our capital stock into which the warrants are convertible), other than (a) as described above, (b) certain ordinary cash dividends, or (c) to satisfy the redemption rights of the holders of Class A Common Stock in connection with the Business Combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Class A Common Stock in respect of such event.
5
If the number of outstanding shares of our Class A Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Class A Common Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class A Common Stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding shares of Class A Common Stock.
Whenever the number of shares of Class A Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Class A Common Stock so purchasable immediately thereafter.
In case of any reclassification or reorganization of the outstanding shares of Class A Common Stock (other than those described above or that solely affects the par value of such shares of Class A Common Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Class A Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of our Class A Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Class A Common Stock in such a transaction is payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes value (as defined in the Warrant Agreement) of the warrant.
The warrants have been issued in registered form under a warrant agreement (the Warrant Agreement) between Continental Stock Transfer & Trust Company, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. If an amendment adversely affects the private placement warrants in a different manner than the public warrants or vice versa, then approval of holders of at least 65% of the then-outstanding public warrants and 65% of the then-outstanding private placement warrants, voting as separate classes, is required.
The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of Class A Common Stock or any voting rights until they exercise their warrants and receive shares of Class A Common Stock. After the issuance of shares of Class A Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.
6
No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of Class A Common Stock to be issued to the warrant holder.
Private Placement Warrants
The private placement warrants will not be redeemable by us (except as described above under Public Stockholders Warrants Redemption of Warrants for Cash When the Price Per Share of Class A Common Stock Equals or Exceeds $10.00) so long as they are held by the initial purchasers of the private placement warrants or their permitted transferees. The initial purchasers, or their permitted transferees, have the option to exercise the private placement warrants on a cashless basis. Otherwise, the private placement warrants have terms and provisions that are identical to those of the public warrants, including as to exercise price, exercisability and exercise period. If the private placement warrants are held by holders other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the public warrants.
If holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of shares of Class A Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value (defined below) by (y) the fair market value. The fair market value shall mean the average reported last sale price of the Class A Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent.
Dividends
We have not paid any cash dividends on the Class A Common Stock to date. We may retain future earnings, if any, for future operations, expansion and debt repayment and have no current plans to pay cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of the Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that the Board may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur.
Certain Anti-Takeover Provisions of Delaware Law and our Charter and Bylaws
Under Section 203 of the DGCL, Hyzon is prohibited from engaging in any business combination with any stockholder for a period of three years following the time that such stockholder (the interested stockholder) came to own at least 15% of our outstanding voting stock (the acquisition), except if:
| the Board approved the acquisition prior to its consummation; |
| the interested stockholder owned at least 85% of the outstanding voting stock upon consummation of the acquisition; or |
| the business combination is approved by the Board, and by a 2/3 majority vote of the other stockholders in a meeting. |
Generally, a business combination includes any merger, consolidation, asset or stock sale or certain other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an interested stockholder is a person who, together with that persons affiliates and associates, owns, or within the previous three years owned, 15% or more of our voting stock.
Under certain circumstances, declining to opt out of Section 203 of the DGCL will make it more difficult for a person who would be an interested stockholder to effect various business combinations with Hyzon for a three-year period. This may encourage companies interested in acquiring Hyzon to negotiate in advance with the Board because the stockholder approval requirement would be avoided if the Board approves the acquisition which results in the stockholder becoming an interested stockholder. This may also have the effect of preventing changes in the Board and may make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.
7
Written Consent by Stockholders
Under the Charter, subject to the rights of any series of Preferred Stock then outstanding, any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of our stockholders and may not be effected by any consent in writing by such stockholders.
Special Meeting of Stockholders
Under the Charter, special meetings of our stockholders may be called only by the chairperson of the Board, the Chief Executive Officer of Hyzon or the Board acting pursuant to a resolution adopted by a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships, and may not be called by any other person or persons. Only such business shall be considered at a special meeting of stockholders as shall have been stated in the notice for such meeting.
Advance Notice Requirements for Stockholder Proposals and Director Nominations
Under the Charter, advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of our stockholders shall be given in the manner and to the extent provided in our Bylaws.
Exclusive Forum
The Charter provides that, unless Hyzon consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, a state court located within the State of Delaware (or, if no court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for any internal or intra-corporate claim or any action asserting a claim governed by the internal affairs doctrine as defined by the laws of the State of Delaware, including, but not limited to (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or stockholders to us or our stockholders; or (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the Charter or the Bylaws (in each case, as they may be amended from time to time), or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware.
Notwithstanding the foregoing, the Charter provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for any action asserting a cause of action arising under the Securities Act or any rule or regulation promulgated thereunder (in each case, as amended) shall be the federal district court for the District of Delaware (or, if such court does not have jurisdiction over such action, any other federal district court of the United States); provided, however, that if the foregoing provisions are, or the application of such provisions to any person or entity or any circumstance is, illegal, invalid or unenforceable, the sole and exclusive forum for any action asserting a cause of action arising under the Securities Act or any rule or regulation promulgated thereunder (in each case, as amended) will be the Court of Chancery of the State of Delaware. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in our shares of capital stock will be deemed to have notice of and consented to the forum provision in the Charter.
Our Transfer Agent and Warrant Agent
The transfer agent for our common stock and warrant agent for our warrants is Continental Stock Transfer & Trust Company.
Listing of Securities
Our Class A Common Stock and public warrants are listed on NASDAQ under the symbols HYZN and HYZNW, respectively.
8
Exhibit 10.18
AMENDED AND RESTATED BOARD OF DIRECTORS AGREEMENT
THIS AGREEMENT is made and entered into effective as of the date set for the below, by and between Hyzon Motors Inc., a Delaware corporation (the Company) with its principal place of business located at 475 Quaker Meeting House Road, Honeoye Falls, NY 14472, and , an individual (Director) with his/her principal residence on file with the Company.
1. | Term |
Subject to the termination provisions set forth in Section 4, this Agreement shall continue until the Companys annual meeting of stockholders (the Initial Term), and should Director be re-elected by the Companys stockholders, shall remain in effect for as long as Director is elected and serving as a member of the Board of Directors (the Board) by the shareholders of the Company (Extended Term).
2. | Position and Responsibilities |
(a) Position. Effective as of July 16, 2021, the Board hereby appoints the Director to serve as a Board member until the expiration of the Initial Term or until his/her earlier resignation, removal or death. Director shall perform such duties and responsibilities as are customarily related to such position in accordance with Companys bylaws and applicable law, including, but not limited to, those services described on Exhibit A attached hereto (the Services). Director hereby agrees to use his/her best efforts to provide the Services. Director shall not allow any other person or entity to perform any of the Services for or instead of Director. Director shall comply with the statutes, rules, regulations and orders of any governmental or quasi-governmental authority that are applicable to the Company and the performance of the Services, Companys rules, regulations, and practices as they may from time-to-time be adopted or modified.
(b) Other Activities. Director may be employed by another company, may serve on other boards of directors or advisory boards, and may engage in any other business activity (whether or not pursued for pecuniary advantage), as long as such outside activities do not violate Directors obligations under this Agreement or Directors fiduciary obligations to the Companys shareholders. The ownership of less than a 5% interest in an entity, by itself, shall not constitute a violation of this duty. Director represents that Director has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, and Director agrees to use his/her best efforts to avoid or minimize any such conflict and agrees not to enter into any agreement or obligation that could create such a conflict without the approval of a majority of the Board of Directors. If, at any time, Director is required to make any disclosure or take any action that may conflict with any of the provisions of this Agreement, Director will promptly notify the Board of such obligation, prior to making such disclosure or taking such action.
(c) No Conflict. Director will not engage in any activity that creates an actual or perceived conflict of interest with Company, regardless of whether such activity is prohibited by
1
Companys conflict of interest guidelines or this Agreement, and Director agrees to notify the Board before engaging in any activity that could reasonably be assumed to create a potential conflict of interest with Company. Notwithstanding the provisions of Section 2(b) hereof, Director shall not engage in any activity that is in direct competition with the Company or serve in any capacity (including, but not limited to, as an employee, consultant, advisor or director) in any company or entity that competes directly or indirectly with the Company, as reasonably determined by a majority of Companys disinterested board members, without the approval of the Board.
3. | Compensation and Benefits |
(a) Directors Fee. In consideration of the services to be rendered under this Agreement, Company shall pay Director an annual fee as provided in Exhibit B.
(b) Stock and Stock Options. Subject to actual grant by the Compensation Committee of the Board of Directors, Director will be granted stock options and Restricted Stock Units (RSUs) as set forth and described on Exhibit B in accordance with the Companys 2021 Equity Incentive Plan (the Plan). The provisions of Exhibit B are incorporated into and made a part of this Agreement.
(c) Expenses. The Company shall reimburse Director for all reasonable business expenses incurred in the performance of the Services in accordance with Companys expense reimbursement guidelines.
(d) Indemnification. Company will indemnify and defend Director against any liability incurred in the performance of the Services to the fullest extent authorized in Companys Articles of Incorporation, as amended, bylaws, as amended, and applicable law. Company will purchase Directors and Officers liability insurance when such policy is purchased by the Company, and Director shall be entitled to the protection of any insurance policies the Company maintains for the benefit of its Directors and Officers against all costs, charges and expenses in connection with any action, suit or proceeding to which she may be made a party by reason of his/her affiliation with Company, its subsidiaries, or affiliates.
(e) Records. So long as the Director shall serve as a member of the Companys Board of Directors the Director shall have full access to books and records of Company and access to management of the Company.
4. | Termination |
(a) Right to Terminate. At any time, Director may be removed as Board member as provided in Companys Articles of Incorporation, as amended, bylaws, as amended, and applicable law. Director may resign as Board member, or as the chair or member of any Board committee as provided in Companys Articles of Incorporation, as amended, bylaws, as amended, and applicable law. The resignation or removal of Director from any Board committee shall not necessarily result in the resignation or removal of the Director from the Board.
2
Notwithstanding anything to the contrary contained in or arising from this Agreement or any statements, policies, or practices of Company, neither Director nor Company shall be required to provide any advance notice or any reason or cause for termination of Directors status as Board member, except as provided in Companys Articles of Incorporation, as amended, Companys bylaws, as amended, and applicable law.
(b) Effect of Termination as Director. Upon Directors termination this Agreement, Company shall pay to Director all compensation and expenses to which Director is entitled up through the date of termination and Director shall be entitled to his/her rights under any other applicable law. Thereafter, all of Companys obligations under this Agreement shall cease.
5. | Directors Termination Obligations |
(a) Director agrees that all property, including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts, and computer-generated materials provided to or prepared by Director incident to the Services and his/her membership on the Companys Board or any committee therefore the sole and exclusive property of the Company and shall be promptly returned to the Company at such time as the Director is no longer a member of the Companys Board.
(b) Upon termination of this Agreement, Director shall be deemed to have resigned from all offices and committees then held with Company by virtue of his/her position as Board member. Director agrees that following any termination of this Agreement, she shall cooperate with Company in the winding up or transferring to other directors of any pending work and shall also cooperate with Company (to the extent allowed by law, and at Companys expense) in the defense of any action brought by any third party against Company that relates to the Services.
6. | Nondisclosure Obligations |
Director shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this Agreement, any Proprietary Information (as defined below), confidential information, or trade secrets belonging to Company, whether or not it is in written or permanent form, except to the extent necessary to perform the Services, as required by a lawful government order or subpoena, or as authorized in writing by Company. These nondisclosure obligations also apply to Proprietary Information belonging to customers and suppliers of Company, and other third parties, learned by Director as a result of performing the Services. Proprietary Information means all information pertaining in any manner to the business of Company, unless (i) the information is or becomes publicly known through lawful means; (ii) the information was part of Directors general knowledge prior to his/her relationship with Company; or (iii) the information is disclosed to Director without restriction by a third party who rightfully possesses the information and did not learn of it from Company.
7. | Dispute Resolution |
(a) Jurisdiction and Venue. The parties agree that any suit, action, or proceeding between Director and Company (and its affiliates, shareholders, directors, officers, employees,
3
members, agents, successors, attorneys, and assigns) relating to this Agreement shall be brought in either the United States District Court for the State of Delaware or in a Delaware state court and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court. If any one or more provisions of this Section shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.
(b) Attorneys Fees. Should any litigation, arbitration or other proceeding be commenced between the parties concerning the rights or obligations of the parties under this Agreement, the party prevailing in such proceeding shall be entitled, in addition to such other relief as may be granted, to a reasonable sum as and for its attorneys fees in such proceeding. This amount shall be determined by the court in such proceeding or in a separate action brought for that purpose. In addition to any amount received as attorneys fees, the prevailing party also shall be entitled to receive from the party held to be liable, an amount equal to the attorneys fees and costs incurred in enforcing any judgment against such party. This Section is severable from the other provisions of this Agreement and survives any judgment and is not deemed merged into any judgment.
8. | Entire Agreement |
This Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning the Agreement.
9. | Amendments; Waivers |
This Agreement may be amended, modified, superseded, or canceled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged. Any amendment or waiver by the Company must be approved by the Companys Board of Directors and executed on behalf of the Company by its Chief Executive Officer. If the Director shall also serve as Chief Executive Officer, such amendment or waiver must be executed on behalf of the Company by an officer designed by the Companys Board of Directors.
10. | Assignment |
This Agreement shall not be assignable by either party.
11. | Severability |
If any provision of this Agreement shall be held by a court to be invalid, unenforceable, or void, such provision shall be enforced to fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court of competent jurisdiction to exceed the maximum time
4
period or scope that such court deems enforceable, then such court shall reduce the time period or scope to the maximum time period or scope permitted by law.
12. | Governing Law |
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.
13. | Interpretation |
This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Captions are used for reference purposes only and should be ignored in the interpretation of the Agreement.
14. | Binding Agreement |
Each party represents and warrants to the other that the person(s) signing this Agreement below has authority to bind the party to this Agreement and that this Agreement will legally bind both Company and Director. To the extent that the practices, policies, or procedures of Company, now or in the future, are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Directors duties or compensation as Board Member will not affect the validity or scope of the remainder of this Agreement.
15. | Director Acknowledgment |
Director acknowledges Director has had the opportunity to consult legal counsel concerning this Agreement, that Director has read and understands the Agreement, that Director is fully aware of its legal effect, and that Director has entered into it freely based on his/her own judgment and not on any representations or promises other than those contained in this Agreement. Director further acknowledges that Company has not provided any legal advice to Director in connection with this Agreement.
16. Mutual Non-Disparagement
Director and the Company mutually agree to forbear from making, causing to be made, publishing, ratifying, or endorsing any and all disparaging remarks, derogatory statements or comments made to any party with respect to either of them. Further, the parties hereto agree to forbear from making any public or non-confidential statement with respect to the any claim or complain against either party without the mutual consent of each of them, to be given in advance of any such statement.
17. | Counterparts |
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
5
EXHIBIT A
DESCRIPTION OF DIRECTORS SERVICES
Responsibilities as Director. Director shall have all responsibilities of a Director of the Company imposed by Delaware or applicable law, the Articles of Incorporation, as amended, and Bylaws, as amended, of Company. These responsibilities shall include, but shall not be limited to, the following:
1. Attendance. Use best efforts to attend scheduled meetings of Companys Board of Directors and any Board Committee on which Director may serve;
2. Act as a Fiduciary. Represent the shareholders and the interests of Company as a fiduciary using his/her best judgment acting foremost in the interests of the Companys shareholders and stakeholders; and
3. Participation. Participate as a full voting member of Companys Board and any Board Committee in setting overall objectives, approving plans and programs of operation, formulating general policies, offering advice and counsel, serving on Board Committees, and reviewing management performance.
4. Committee Chair. [Reserved]
5. Other.
(a) Director acknowledges and agrees that the Company may rely upon Directors expertise in product development, marketing, or other business disciplines where Director has a deep understanding with respect to the Companys business operations and that such requests may require substantial additional time and efforts in addition to Directors customary service as a member of the Board.
(b) Director will notify the Company promptly if she is subpoenaed or otherwise served with legal process in any matter involving the Company or its subsidiaries. Director will notify the Company if any attorney who is not representing the Company contacts or attempts to contact Director (other than Directors own legal counsel) to obtain information that in any way relates to the Company or its subsidiaries, and Director will not discuss any of these matters with any such attorney without first so notifying the Company and providing the Company with an opportunity to have its attorney present during any meeting or conversation with any such attorney.
7
EXHIBIT B
DIRECTORS FEES, STOCK OPTIONS, RSUs AND VESTING
Cash Compensation
Annual Fee
The Annual Fee shall be $ , paid annually. The Annual Fee will be prorated based on number of months active service, rounded to the nearest whole month of service. The Annual Fee will be paid quarterly in arrears.
The following example illustrates application of these provisions:
Example:
Director is appointed to the board effective July 16, 2021, and serves for the entire calendar year. Directors initial Annual Fee shall be $ [(July through December/12 months) * $ ]. Director will receive $ for each quarter or portion thereof. The Annual Fee shall be payable in arrears on the first business day of the first month of each quarter.
Committee Chair Fee: [Reserved]
Equity Compensation
New Hire Equity Award
Subject to actual grant by the Compensation Committee and the terms and conditions in the Companys 2021 Stock Incentive Plan and an individual award agreement between the Company and Director, Director will be granted Options and RSUs as further described herein with a combined value of $ , with the Options determined using the Black Scholes formula (the New Hire Equity Grant). The New Hire Equity Grant shall be comprised of the following:
Equity Type | Percentage | |
Options | 50% of $ | |
RSUs | 50% of $ |
1. | The Options and RSUs will be subject to 3-year vesting, where 1/3rd of the Options and RSUs will vest upon each of the one-year, two-year and three-year anniversary of the November 11, 2021, subject to continued service through each such date. 1/3 of the Options will be exercisable from the first anniversary of the grant date. |
2. | Options will expire five years from the date of issue. |
8
3. | The Company shall provide a cashless (net settlement) exercise procedure. |
Annual Equity Award
Subject to actual grant by the Compensation Committee and the terms and conditions of the Companys 2021 Stock Incentive Plan and an individual award agreement between Company and Director, subject to Directors ongoing service with the Companys Board of Directors, on the date of each Company Annual Meeting of Shareholders, Company will grant Director Options and RSUs with a combined value of $ ; the number of Options shall be determined using the Black Scholes formula (the Annual Equity Grant). The Annual Equity Awards shall be comprised of the following:
Equity Type | Percentage | Number of Options/RSUs | ||
Options | 50% | Based on Black Scholes Formula on date of grant or date prior to the date of grant | ||
RSUs | 50% | Based on closing price on date of grant or date prior to the date of grant |
The Annual Options and RSUs will vest in full on the first anniversary of the grant date, subject to Directors ongoing service. The options are exercisable for five years from the first anniversary of the grant date.
9
Exhibit 21.1
HYZON MOTORS INC.
LIST OF SUBSIDIARIES
(As of December 31, 2021)
Entity |
Jurisdiction of Incorporation or Organization | |
Hyzon Motors USA Inc. |
Delaware | |
Hyzon Zero Carbon, Inc. |
Delaware | |
Hyzon Motors Fleet LLC |
Delaware | |
Hyzon Motors Australia PTY LTD |
Australia | |
Hyzon Motors Europe B.V. |
Netherlands | |
Hyzon Motors UK LTD |
United Kingdom | |
Hyzon Motors Innovation GmbH |
Germany | |
Hyzon Motors PTE. LTD. |
Singapore | |
Hyzon Automobile Technology (Shanghai) Co., Ltd. |
China | |
Foshan New Energy Technology Co., Ltd. |
China | |
Hyzon Motors Technology Guangdong Co Ltd. |
China |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements on Form S-1 (No. 333-258340) and Form S-8 (No. 333-259674) of our report dated March 30, 2022, with respect to the consolidated financial statements of Hyzon Motors Inc.
/s/ KPMG LLP
Rochester, New York
March 30, 2022
Exhibit 31.1
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Craig Knight, certify that:
1. | I have reviewed this Annual Report on Form 10-K of Hyzon Motors Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 30, 2022
/s/ Craig Knight |
Craig Knight Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark Gordon, certify that:
1. | I have reviewed this Annual Report on Form 10-K of Hyzon Motors Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 30, 2022
/s/ Mark Gordon |
Mark Gordon Chief Financial Officer (Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Hyzon Motors Inc. (the Company) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Craig Knight, Chief Executive Officer and Director of the Company, hereby certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 30, 2022
/s/ Craig Knight |
Craig Knight Chief Executive Officer (Principal Executive Officer) |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Hyzon Motors Inc. (the Company) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mark Gordon, Chief Financial Officer and Director of the Company, hereby certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 30, 2022
/s/ Mark Gordon |
Mark Gordon Chief Financial Officer (Principal Financial Officer) |